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ABSTRACT
Orellana, Esteban A. Ph.D., Purdue University, March 2018. Enhancing miRNA
therapeutic efficacy through combinatorial targeting and vehicle free delivery. Major
Professor: Andrea L. Kasinski.
New alternative therapies to treat cancer have emerged such as the use of small
molecules that target key oncogenic drivers. For instance, clinically relevant tumor
suppressive microRNAs (miRNAs) that target key oncogenic drivers have been
identiﬁed as potential therapeutics to treat cancer. MiRNAs are small non-coding
RNAs that negatively regulate gene expression at the posttranscriptional level. It
has been shown that aberrant miRNA expression, through misexpression of miRNA
target genes, can have profound cellular e↵ects leading to a variety of diseases,
including cancer. While altered miRNA expression contributes to a cancerous state,
restoration of miRNA expression has therapeutic beneﬁts. For example, ectopic
expression of miRNA-34a (mir-34a), a tumor suppressor miRNA that is a direct
transcriptional target of p53 and thus is reduced in p53 mutant tumors, has clear
e↵ects on cell proliferation and survival in murine models of cancer. It is expected
that miRNA replacement therapies will have profound e↵ects in the clinic; however,
miRNA therapeutics are still in their infancy and there are critical challenges that
need to be addressed for the advancement of miRNA-based therapies. Firstly, one of
the biggest challenges for miRNA advancement into the clinic is efficient delivery of
miRNA mimics due to problems such as delivery-associated toxicity, poor
transfection, systemic clearance, poorly understood biodistribution, degradation in
circulation, immune response, and endosomal sequestration. Secondly, strategies to
enhance the therapeutic efficacy of a miRNAs, such as through combinatorial
miRNA therapeutics, have yet to be explored meticulously.

xiv
Therefore, there is a critical need to identify strategies to overcome these obstacles
and facilitate the advancement of miRNA therapies into clinical trials. For that
reason, we hypothesized that a ligand targeted miRNA strategy could be used for
successful delivery of therapeutic miRNAs into target tissues. Furthermore, since
miRNAs can regulate multiple gene targets we also hypothesized that two or more
miRNAs could potentially collaborate to repress the expression of numerous cancerrelated genes in various pathways. The results presented here show i) that unprotected
functional miRNA mimics can be delivered to solid tumors using vehicle free ligandmediated delivery, ii) that the implementation of endosomal escape mechanism helps
to increase targeting efficacy leading to a reduction in the e↵ective dose and iii)
that miRNA combinations have enhanced efficacy for lung cancer. Collectively these
studies will address an unmet need of identifying, characterizing, and therapeutically
targeting miRNAs for the treatment of cancer.
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1. INTRODUCTION
The following publication (Orellana and Kasinski, 2015) is an open access article
distributed under the Creative Commons Attribution License which permits
unrestricted use, distribution, and reproduction in any medium (CC BY 4.0).

1.1

MicroRNAs in Cancer: A Historical Perspective on the Path from
Discovery to Therapy
MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) that are recognized

as important members of the post-transciptional regulatory arsenal within a cell. As
such, tight control of miRNA expression and processing is crucial to maintain normal
cellular functions and homeostasis. The functional importance of miRNAs has been
reported not only in normal biological processes but also in human diseases such as
cancer. Herein miRNA biology, the role of miRNAs in disease and the potential
therapeutic use of miRNAs will be discussed.

1.1.1

Early History: MiRNA Discovery

The history of microRNAs started with basic research in microscopic worms. In
the mid 1970s, Sydney Brenner was studying neural development in Caenorhabditis
elegans and during his screening of mutant worms isolated the ﬁrst nematode that
had a developmental timing defect (heterochronic mutant) named lin-4 (cell lineage
abnormal) [90, 13].

This particular discovery has led to insights of substantial

importance to human biology and disease. In the early 1980s, Robert Horvitz who
worked as a postdoctoral research fellow in the Brenner lab along with John
Sulston, a sta↵ scientist also in the same laboratory, characterized lin-4 during the
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inspiring quest to understand how the temporal development pattern in animals is
controlled [69]. It was determined that the abnormal lineage was a result of a null
mutation (e912) in the heterochronic gene lin-4 that caused abnormal temporal
development [69, 23]. Individual worms bearing the lin-4(e912) mutation ultimately
develop an abnormal adult phenotype; the worms reiterate late larval stage cell
fates and thus are incapable of laying eggs [69, 23].
In 1984, Victor Ambros, a postdoctoral fellow in the Horvitz lab, worked to
characterize heterochronic mutants of C. elegans, and found another heterochronic
mutant lineage in null lin-14 mutants that presented an opposing phenotype to lin-4
(e912) [2], animals skipped early fates and instead produced later fates precociously.
Later, in 1987, Horvitz and colleagues, Edwin Ferguson and Paul Sternberg,
reported that null mutations in the lin-14 gene reversed the phenotype seen in lin-4
loss of function [50]. These intriguing observations suggested an epistatic interaction
in which lin-4 negatively regulates lin-14. The initial assumption was that the gene
product of lin-4 was most likely a protein acting as a negative regulator of lin-14;
however, this would be proven incorrect during the following years. Victor Ambros
and Gary Ruvkun, both trained in the Horvitz lab, now as principal investigators in
their own laboratories continued their research characterizing the lin-4-lin-14
interaction.

In 1993, two independent and mutually reinforcing studies were

published in the same issue of Cell as a result of sharing ideas and unpublished
results. First, Rosalind Lee and Rhonda Feinbaum working in the Ambros’ lab
demonstrated that the genomic locus that contained lin-4 did not encode a protein
[92].

Instead, Ambros and colleagues, identiﬁed two small non-coding lin-4

transcripts of 22 and 61 nt respectively [92]. In the other publication, Ruvkun along
with Bruce Wightman and Ilho Ha identiﬁed seven elements in the 3 untranslated
region (UTR) of lin-14 that had sequence complementarity to the lin-4 small RNAs
[184]. These two independent studies had discovered a novel mechanism in which
lin-4 mediated its e↵ects on lin-14 through a posttranscriptional mechanism via an
antisense RNA duplex interaction [92, 184].

The work that initiated with the
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identiﬁcation of heterochronic C. elegans mutants led to the unexpected discovery
of an entirely new type of regulatory mechanism mediated by a non-coding RNA
and established a new paradigm that challenged the central dogma in biology (see
Figure 1.1 for an extensive view of the progression of the miRNA ﬁeld beginning
with the work of Ambros and Ruvkun).
For seven years there were no signs that similar non-coding RNA regulatory
mechanisms existed in C. elegans or any other metazoan. That changed in 2000,
when the Ruvkun laboratory reported they had identiﬁed a second heterochronic
gene in nematodes, lethal-7 (let-7 ), that did not encode a protein product but
rather produced a 22 nt RNA [146, 159]. Similarly to lin-4, the let-7 regulatory
RNA was essential for cell fate transitions from the larval to adult stages.

In

February of 2000, Brenda Reinhart and Frank Slack in Ruvkuns lab demonstrated
that loss of let-7 causes transformations in which larval cellular fates are reiterated,
while increased levels of let-7 leads to omission of larval-speciﬁc events [146]. In
April of the same year, Frank Slack and colleagues discovered that let-7 activation
during late larval stages regulates the nematode larval-adult transition by
downregulating its target LIN-41, which in turn negatively regulates LIN-29, a
transcription factor that controls of adult speciﬁcation [159].

Only a few short

months later, Amy Pasquinelli and her colleagues in the Ruvkun laboratory
reported that they had identiﬁed let-7 RNA homologues in multiple animal species
including humans and other model organisms [137]. The developmental regulation
mediated by let-7 was shown to be conserved among other species including
Drosophila and zebraﬁsh, suggesting that the mechanism mediated by the small
non-coding RNA let-7 was conserved through evolution [137].
By the year 2000, the Ambros and Ruvkun laboratories had discovered the two
founding members of a family of small non-coding RNAs, now called microRNAs
(miRNAs), a rather large family with members not only in nematodes but also
widespread in insects, plants and mammals [137, 91, 86, 84, 147]. These seminal
discoveries were followed in 2001 by three independent studies that provided further
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support that miRNAs were indeed conserved through evolution, and that other
miRNAs were present in invertebrates and mammals implying that miRNA
functions could be a general gene regulatory mechanism in eukaryotes [91, 86, 84].

1.2

miRNA Biology

1.2.1

miRNA Biogenesis

In early 2000s, these newly discovered small RNAs started to be recognized as
important members of the gene regulatory arsenal within a cell. However, their
biogenesis was still obscure. The detection of miRNA transcripts of di↵erent sizes
(22 and 61 nt) suggested that the 22 nt transcripts originated from larger precursor
transcript [92, 146, 137, 147]. In 2001, a mechanism for miRNA processing was
documented for the ﬁrst time by Mello, Ruvkun, and Zamore. Mechanistically, the
immature form (pre-miRNA, 60 to 110 nt) was processed by the cytoplasmic
enzyme Dicer into a short miRNA duplex (⇠20 nt, dsRNA) [57, 70]. Very shortly
thereafter, it was demonstrated that some miRNAs are transcribed as longer
primary transcripts (pri-miRNAs), which are typically capped and polyadenylated
[17]. These pri-miRNAs are processed into a mature form through a controlled and
sequential process [93]. In 2003, Lee and colleagues identiﬁed a human nuclear
RNase III termed Drosha that was responsible for initiation of the miRNA
maturation process [94].

The authors showed that Drosha mediated nuclear

processing of pri-miRNA transcripts into 70 nt pre-miRNAs [94]. Altogether these
studies

demonstrated

that

miRNA

maturation

was

a

sequential

and

compartmentalized process: (i) generation of pre-miRNAs from pri-miRNAs in the
nucleus by Drosha and (ii) processing of pre-miRNAs into mature miRNAs in the
cytoplasm by Dicer.

The fact that the two sequential steps occurred in two

subcellular localizations suggested that pre-miRNAs had to undergo nuclear export,
but the underlying mechanism was still unknown. That changed in 2004, when
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Elsebet Lund and colleagues reported that the nuclear karyopherin exportin-5
mediates efficient export of pre-miRNAs from the nucleus into the cytoplasm [106].

1.2.2

miRNA Biological Function

The knowledge necessary to understand how these miRNAs work was acquired
from the study of the RNA interference (RNAi) phenomenon initially identiﬁed in
plants. RNA silencing in plants was determined to be mediated by dsRNAs of
⇠21-23 nt (small interfering RNAs, siRNAs) with sequence complementarity to the
target mRNA which triggers mRNA cleavage [197]. This phenomenon, reported in
2000, was followed in the same year with the discovery of the mechanism leading to
mRNA degradation.

Scott Hammond and colleagues demonstrated that RNAi

targeted mRNA degradation through the formation of a sequence-speciﬁc nuclease
that they termed RISC (RNA-induced silencing complex).

Single strand RNA

species derived from both miRNAs and siRNAs (dsRNAs) were determined to be
the signature component of RISC [61].
In regards to miRNA target speciﬁcity, in 2003 an approach was described to
predict mammalian miRNA targets based on sequence pairing to the 50 end of the
miRNA, particularly nucleotides 2-8, which was referred as the miRNA seed
sequence [97].

This came from the elucidation that miRNA-mRNA binding

identiﬁed in this study was based on perfect complementarity only within the seed
region; the remaining sequence of the miRNA paired imperfectly with the target.
From a historical perspective, the study and identiﬁcation of miRNA gene targets
was limited to the identiﬁcation of the complementary sequence of the miRNA seed
in the 30 UTR of mRNAs. That changed in 2007 when Robin Lytle and colleagues
published the ﬁrst report suggesting that miRNAs could also bind to the 50 UTR
and exert gene repression [109]. The following ﬁndings showed that miRNAs could
also bind to the coding sequence (CDS) of their target genes [168].

While the

seed-binding hypothesis is incorporated into many miRNA-mRNA binding
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algorithms and is further used to classify miRNAs into families, recent studies
suggest seed-independent binding.

In 2013 Aleksandra Helwak and colleagues

developed an elegant experimental approach to identify targets of miRNAs in vivo
and reported that indeed most miRNA-mRNA interactions include the seed region;
however, more that 60% of seed interactions contain mismatched nucleotides and
bulges, suggesting seed-independent interactions [67]. Even more interesting, they
describe a data set of more than 18,000 miRNA-mRNA interactions in which ⇠42%
of interactions occur in the CDS, ⇠23% in the 30 UTR, and ⇠4% in the 50 UTR,

further supporting the hypothesis that miRNAs could control protein production by
binding targets outside of the 30 UTR [67].
MiRNAs were primarily associated with negative posttranscriptional regulation of
gene expression, which could be achieved by blocking translation or causing mRNA
degradation, but the contributions of each mechanism remained obscure. In 2010,
Huili Guo and colleagues found that destabilization of mRNAs account for more than
84% of the decreased protein output [59]. Far less understood functions of miRNAs
have also been reported. For instance, miRNAs have been shown to activate protein
translation in certain cellular contexts [49, 176, 140], act as decoys for regulatory
proteins [43] and could function in RNA crosstalk [167, 150].

1.3

MiRNA Misregulation in Cancer
From all the insights gained from the study of miRNAs in C. elegans

development it was evident that tight control of miRNA expression and processing
was crucial to sustain normal cellular functions and homeostasis. In 2002, only two
years after the discovery of the ﬁrst human miRNA (let-7 ), the ﬁrst report
suggesting the involvement of miRNAs in cancer was published. George Calin and
colleagues, working in Carlo Croces laboratory attempted to ﬁnd tumor suppressor
genes within a chromosomal region (13q14) that is often deleted in patients with B
cell chronic lymphocytic leukemia (B-CLL) [19].

Instead of ﬁnding a canonical
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tumor suppressor gene that encodes a protein, they found that this region harbored
two miRNA genes, mir-15a and mir-16-1 [19]. For the ﬁrst time in the brief history
of miRNAs researchers had demonstrated the consistent involvement of two
miRNAs in B-CLL, where both miRNAs are either deleted or downregulated,
suggesting their potential role as tumor suppressors [19]. Later, in a follow-up study,
the same research group mapped 98 miRNAs to locations previously reported to be
associated with genetic alterations either involved in cancer or contained in fragile
sites of the genome [21].

Similarly, the ﬁrst indication that miRNAs may also

function as oncogenes was reported by He, Thomson and colleagues in 2005. In the
ﬁrst of its kind experiment, overexpression of the polycistronic transcript encoding
the miR-17⇠92 cluster in vivo, which is overexpressed in patients with B-CLL,
demonstrated that these miRNAs could enhance lymphoma in a mouse model
induced by the c-Myc oncogene [65]. These oncogenic miRNAs have since been
termed oncomiRs.

These seminal studies provided several indications of the

involvement of miRNAs in human cancers and paved the path to understand the
importance of miRNAs in tumorigenesis and other diseases.
Although, the biological importance of miRNAs started to become apparent by
mid 2000s, still very little was known about the regulatory mechanisms that control
miRNA expression. In 2005, Kathryn O’Donnell and colleagues reported that the
transcription factor c-MYC, one of the most common oncogenes in human neoplasms,
was able to regulate the expression of the miR-17⇠92 cluster [127]. Similarly, p53,
the most commonly mutated tumor suppressor gene in human cancers, was identiﬁed
as a transcriptional regulator of the miR-34 family of miRNAs. Five independent
groups identiﬁed that the three miR-34 genes, mir-34a, mir-34b, and mir-34c, the
later two expressed from one transcript, were transcriptionally regulated by p53 and
that these small RNAs could compensate for some of the tumor suppressive function
of p53. Collectively, these studies, revealed for the ﬁrst time in the vast history of
p53 biology, that miRNAs were a core component of the tumor suppressive role of
p53 [9, 24, 66, 145, 165].
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In addition to regulation of miRNA genes by transcription factors, miRNAs were
also found to be modulated by epigenetic mechanisms. In 2006, Yoshimasa Saito
and colleagues demonstrated that both DNA methylation and histone modiﬁcation
play a role in regulating expression of miRNAs, particularly mir-127. Mir-127 is
often silenced in cancer cells; however in the presence of chromatin-modifying drugs
(i.e., DNA-demethylating agents and histone deacetylase inhibitors) miR-127 is
highly induced from its own promoter [149]. A similar situation was observed for
mir-34a. While, loss of p53 can lead to reduced expression of miR-34a, mir-34a is
also regulated by promoter methylation. All tumor types analyzed in the study had
appreciable levels of methylation at the mir-34a promoter that resulted in
diminished miR-34a expression [102]. From 2002 to the present, a myriad of studies
have conﬁrmed that miRNA deregulation is a hallmark of cancers as a result of
mutations, deletions, ampliﬁcations, and dysregulation of transcriptional regulatory
cascades and processing machinery (For a detailed review see [39, 64]).
In the early 2000s, apart from few exceptions, the roles and functions of most
miRNAs were still unknown. In 2003, the ﬁrst tangible evidence addressing the
involvement of a miRNA in controlling cell cycle progression was published. Julius
Brennecke and colleagues reported that the bantam gene in Drosophila encoded a
miRNA capable of promoting tissue growth by targeting the pro-apoptotic gene hid
thus playing a role in cell progression and apoptosis [12]. It was not until 2005 that the
ﬁrst reports of miRNAs’ mechanistic role in cancer came to light. Steven Johnson and
colleagues, working in Frank Slack’s laboratory provided evidence that let-7 targeted
the 30 UTR of RAS, an important oncogene driving multiple cancers [73]. Indeed, the
authors demonstrated that the three human RAS genes had complementary binding
sites for let-7, showed that let-7 could mediate RAS inhibition in vitro, and showed the
anti-correlation of lower expression of let-7 with over expression of RAS in lung cancer
[73]. In the same year, in another scientiﬁc communication from the Croce lab, leading
author Amelia Cimmino reported that mir-15a and mir-16-1 negatively regulate the
antiapoptotic B cell lymphoma 2 gene (Bcl2 ) causing CLL cells to undergo apoptosis
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[35]; therefore, contributing the missing functional piece of evidence related to the
initial identiﬁcation of mir-15a⇠mir-16-1 genomic loss made by the same laboratory
in previous years [19].
In 2007-2008, miRNAs were shown to play a dual role in tumor invasion and
metastasis. On one hand, miRNAs could promote tumor metastasis, speciﬁcally
mir-10b, as demonstrated by Li Ma working in Robert Weinberg laboratory [111].
This research group unraveled a mechanism in which mir-10b positively regulates
cell migration and invasion in a non-metastatic breast cancer cell line in a
multi-step process that ultimately leads to activation of RHOC, a pro-metastatic
gene [111]. On the other hand, in 2008 a set of miRNAs capable of suppressing
metastasis in vivo via ectopic restoration were identiﬁed. In brief, Sohail Tavazoie
and colleagues described how mir-126 inhibits metastasis by suppressing tumor
growth and proliferation whereas mir-335 and mir-206 achieve the same e↵ect by
regulating migration and changing morphology [166].

In 2009, the ﬁrst in vivo

evidence implicating the overexpression of a miRNA in cancer was communicated.
Costinean, Sandhu and other colleagues from the Croce lab reported that mir-155
directly caused a leukemic phenotype in a mouse model overexpressing a mir-155
transgene [38]. The following year the Slack group reported an astonishing ﬁnding
that a single oncogenic miRNA, mir-21, was enough to cause neoplastic
development in a mouse model with no predisposing mutations [54]. Moreover, the
authors showed that the tumors decreased in size and survival was restored when
mir-21 overexpression was shut down [115]. This evidence suggested that tumors
could become addicted to mir-21 in a phenomenon similar to oncogene addiction
(oncomiR addiction) [115].
While the elucidation of miRNA involvement in cancer was increasing, early
reports in 2008 showed that miRNAs could also be found in circulation
[120, 31, 87, 27], but the speciﬁc mechanisms conferring their stability or their
functional roles were still unknown.

The most widely accepted model in the

literature was that miRNAs in circulation were protected within nanovesicles
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(known as exosomes).

Later studies reported in 2011 by Jason Arroyo and

colleagues determined that miRNAs, besides being encapsulated in exosomes, could
also be found associated with protein complexes, speciﬁcally Argonaute 2, a
member of RISC [5]. This discovery raised the possibility that circulating miRNAs
could still have a functional role. In support of this, exosomes secreted by lung
tumor cells were shown to have a di↵erent miRNA composition than the miRNA
signature from exosomes derived from normal non-malignant cells [48].

Tumor

secreted exosomes, for instance, contained oncogenic miRNAs such as, mir-21,
mir-27b, and mir-29a [48]. In addition to repressing target genes in cells that took
up the miRNA-loaded exosomes, Croce and colleagues demonstrated that exosomal
mir-21 and mir-29a can bind to toll-like receptors (TLRs) and act similar to
hormones to trigger inﬂammatory responses [60]. This speciﬁc aspect of miRNA
biology, previously unknown to science, suggested the possibility that miRNAs
could act as regulators of the tumor microenvironment. In 2014, Sonia Melo and
colleagues provided further evidence supporting this hypothesis showing that
miRNAs present in breast cancer exosomes can enter normal cells and induce
transcriptome alterations that lead to tumor formation [117].

Furthermore, the

authors showed that breast cancer secreted exosomes contain the cellular machinery
necessary to process pre-miRNAs into mature miRNAs demonstrating for the ﬁrst
time cell independent miRNA biogenesis [117].

1.4

MiRNA Transition into Therapy

1.4.1

Diagnosis, Detection and Prognosis

One of the most challenging aspects of the ﬁght against cancer is to detect cancer
accurately and early. For this purpose, multiple research groups around the world are
focusing on the identiﬁcation of potential biomarkers that could be used not only to
detect cancer but also to obtain better prognostic values to classify patients both in
terms of the mutations and potential response to therapies.
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In the case of miRNAs, in 2004 the potential clinical utility of let-7 as a
prognostic tool in human lung cancers was communicated [164]. The Takamizawa
group described an inverse correlation between postoperative survival in patients
with lung cancer and let-7 levels [164]. The following year Calin and colleagues
identiﬁed a 13 miRNA signature that could distinguish patients with CLL and
determined a link with disease prognosis and progression [20]. Around the same
time, Jun Lu and colleagues determined that it was possible to classify cancers
according to their developmental lineage and stage by comparing only miRNA
expression proﬁles [104].

Similarly, in 2008 a pan-cancer miRNA signature was

identiﬁed using The Cancer Genome Atlas miRNA sequencing data from 12 types of
tumors.

Interestingly, the authors describe a pan-tumor miRNA signature

consisting of a miRNA superfamily that includes seven miRNA families targeting
tumor suppressive genes using a GUGC core motif [60]. These ﬁndings further
highlight the potential of miRNAs as biomarkers for cancer.
Many applications have emerged from the discovery of nucleic acids in
circulation [53]. In 2008, reports from independent studies showed that miRNAs
could also be found in circulation [120, 31, 87, 27], thus opening a window to
develop novel approaches to detect cancer through miRNAs in body ﬂuids. In a
proof of principle study, Patrick Mitchell and colleagues, reported that miRNAs are
highly stable in serum and provided direct evidence that miRNAs can indeed enter
the circulation when originated from tumors of non-hematopoietic origin [120]. Such
characteristics make miRNAs particularly appealing for the development of new
diagnostic tools along with minimally invasive biopsies. Indeed, miRNAs in both
tumor tissues and plasma were shown to harbor predictive, diagnostic and
prognostic potential. In this study, the miRNAs signature could predict lung cancer
development and aggressiveness even 1-2 years before diagnosis using computed
tomography [8]. The diagnostic value of miRNAs has gained additional support
from multiple ﬁndings, suggesting potential functional roles of circulating miRNAs
[48, 117].
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Besides the miRNA signatures, the mutational status of miRNA binding sites in
their protein coding targets can also be regarded as a diagnostic tool. Lena Chin, a
graduate student at the time in the Slack laboratory, identiﬁed a KRAS variant
allele that harbors a single nucleotide change (SNP) in a region of the 30 UTR that
contains a let-7 binding site [32]. Patients carrying this mutant allele of KRAS had
a higher risk of developing non-small cell lung cancer (NSCLC) [32]. This initial
KRAS SNP has since been found and validated as a marker of risk in multiple
tumor types, including colorectal [151, 155], head and neck squamous cell carcinoma
[34, 15], endometrial cancer [89], breast and ovarian cancer [139, 22] and others.
The ﬁnding that mutations in miRNA binding sites could a↵ect cancer etiology and
disease development represents a new paradigm in the ﬁeld that until now focused
on identifying mutations only in the coding region of genes.

1.4.2

MiRNAs as Therapeutic Agents

MiRNA aberrant expression in cancer is supported by strong evidence, and
depending on the status and function of a speciﬁc miRNA the therapeutic strategy
could be divided into two main classes: inhibition or replacement.
From a historical standpoint, miRNA inhibition was the ﬁrst approach used to
explore the potential of miRNAs in cancer therapy. It started by an observation in
Zamores group in 2004, in which they showed that it was possible to inhibit let-7
function in C. elegans by introducing a 20-O-methyl oligonucleotide, an RNA
analogue, complementary to let-7 hence acting as an antisense inhibitor [71]. The
following year, Jan Krtzfeldt’s team successfully tested the potential of miRNA
antagonists (termed antagomiRs) in mice and showed that antagomiRs could be
used to block endogenous miRNA activity [82].

For instance, delivery of an

antagomiR targeting mir-122, a highly abundant miRNA in liver involved in
fatty-acid metabolism and hepatitis C virus replication, resulted in de-repression of
mir-122 target genes in the liver of mice [82]. In 2008, miR-122 antagomiRs were

14
further validated in non-human primates [44].

In this case, Joacim Elmn and

colleagues used an RNA analogue formulated with locked-nucleic-acid (LNA)
modiﬁed nucleotides [44]. The authors showed that the LNA-antagomiR was able to
antagonize mir-122 efficiently and in a dose dependent manner, leading to decreased
levels of cholesterol in plasma [44]. Interestingly, the LNA-antagomiR was highly
stable in plasma and no signs of toxicity associated with the LNA modiﬁcation were
observed.

Functionally, the clinically adaptable miravirsen (SPC3649), an

antagomiR targeting mir-122, is able to bind to the stem loop of miR-122 precursors
hence blocking both Dicer and Drosha processing [54]. Miravirsen became the ﬁrst
miRNA-targeting drug that entered clinical trials in 2010 and is currently in phase
II to treat patients with chronic hepatitis C (ClinicalTrials.gov Identiﬁer:
NCT02031133).
Although early research in the antagomiR ﬁeld was done focusing in liver
disease, the experience gained from such studies served as the foundation for the
development of oncomiR inhibitors as an emerging therapeutic approach to control
cancer.

In 2010, Weinberg and colleagues showed for the ﬁrst time that

therapeutically targeting an oncomiR has clinical utility.

The Weinberg group

showed that an antagomiR targeting the pro-metastatic miR-10b could antagonize
metastasis in a murine model of breast cancer [110].

Similarly, in a recent

publication, the Slack group introduced a novel strategy to efficiently inhibit
miR-155, an oncomiR in a murine model of lymphoma, by using a peptide nucleic
acid antagomiR attached to a pH-induced transmembrane structure (pHLIP) [29].
This delivery method takes advantage of the acidic environment of tumors, and
overcomes some of the main challenges of antagomiR delivery by not being cleared
by the liver and entering cells independently of endocytosis [29]. Various modiﬁed
antagomiRs are being developed and are currently in preclinical phase showing
promising results and are predicted to have a broad impact on the ﬁeld of oncomiR
inhibition.
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The second strategy of miRNA therapeutics is to use miRNAs as a therapeutic
agent as a replacement strategy. Ectopic replacement of tumor suppressive miRNAs
aims to restore the miRNA level in cells and tissues with reduced miRNA expression
with the ultimate goal of blocking cellular pathways that drive oncogenesis. One
mechanism to deliver miRNAs into cells is through the use of viral vehicles that
carry the primary miRNA gene and exploit the cellular machinery to transcribe a
pri-miRNA that is further processed into its mature form. Other approaches to
deliver miRNAs that do not require processing to function use miRNA synthetic
mimics, which resemble the mature miRNA duplex (similar to siRNAs) and thus are
recognized by RISC [40].
In 2008, in a proof of principle study, Aurora Esquela-Kerscher and colleagues
demonstrated for the ﬁrst time that restoration of let-7b was able to inhibit lung
cancer in vivo in an orthotopic mouse lung cancer model expressing KrasG12D , an
activating mutation for Kras. This work provided strong evidence that let-7b works
as a tumor suppressor in the lung and demonstrated the potential of let-7b as a
potential miRNA-based therapeutic to treat lung cancer [47]. In 2009, Janaiah Kota
and colleagues determined that restoration of mir-26a, a miRNA that is strongly
downregulated

in

liver

tumors,

via

systemic

delivery

mediated

by

an

adeno-associated virus (AAV) suppresses tumor formation in a Myc-induced mouse
model of liver carcinoma [80]. Interestingly, the fact that mir-26a does not target
MYC for repression suggests that miRNAs could be used as a therapy for cancer
even if they do not target the initiating oncogene [80]. In 2010, Jason Wiggins and
colleagues tested mir-34a, a key regulator of tumor suppression [9, 24, 66, 145, 165],
in vivo using a synthetic mimic and a lipid vehicle and showed that ectopic mir-34a
blocks tumor growth in a xenograft model of lung cancer [183]. Remarkably, this
study provided proof-of-principle for the successful delivery of miRNA mimics
systemically obviating the use of viral vehicles.

This was further supported by

follow up studies conducted by the Slack group. In 2011, mir-34a was delivered
using a neutral lipid emulsion in a murine model of non-small cell lung cancer
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(NSCLC) driven by KrasG12D , which lead to a decrease in tumor burden [171].
Similarly, in 2012, Andrea Kasinski, working in the Slack laboratory, demonstrated
that lentiviral delivered miR-34a prevents both cancer initiation and progression in
an aggressive mouse model of NSCLC that recapitulate the most common
mutations in human lung cancers, loss of p53 and activation of KRAS [77].
It is thus no surprise, based on the pre-clinical data using miR-34a, that in April
of 2013, mir-34a was the ﬁrst miRNA that reached phase I clinical trials
(ClinicalTrials.gov Identiﬁer: NCT01829971) in patients with liver cancer sponsored
by Mirna Therapeutics (Austin, TX, USA). Mirna Therapeutics’ MRX34, is a
mir-34a mimic encapsulated in a liposome vesicle developed by Marina Biotech
(Bothell, WA, USA) [10]. Nonetheless, in 2016 the clinical trial was terminated
prematurely due to immune-related adverse events that involved the death of ﬁve
patients. The cause of these immune reactions in humans has not been determined
yet.

More pre-clinical studies are needed to understand which component of

MRX34, the vehicle or the miRNA, (or both) caused these adverse e↵ects.
There are other companies such as Regulus Therapeutics (San Diego, CA, USA),
Sanoﬁ (Paris, France), miRagen Therapeutics (Boulder, CO, USA) that are also
conducting preclinical studies and have identiﬁed promising miRNAs candidates
that are currently being developed. Recent studies showed that it was possible to
further enhance miR-34a’s anti tumorigenic activity using a combinatorial approach.
Such combinatorial therapies include combinations of di↵erent miRNAs [76],
miRNA-siRNA combinations [187] and miRNA-targeted drug combinations [162].
Collectively these studies have opened a window to the new exciting ﬁeld of
combinatorial therapeutics with miRNAs that will likely further facilitate the
transition of miRNAs into the clinic.
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1.4.3

Closing Remarks

Many pioneer studies over the past twenty-two years have established the
importance of miRNAs in normal cellular homeostasis and repeatedly have
demonstrated the potential of miRNAs as cancer therapeutics.

One point that

emerges from the brief history of miRNAs is that the detailed study of their biology
will lead to new ﬁndings of importance to understand cancer and potential
strategies to control it. Indeed, notable progress has been made in the last 13 years
since the discovery of miRNAs role in cancer. However, miRNA-based therapeutics
and diagnoses are still in their infancy and there are important challenges that the
scientiﬁc community still needs to address. Currently one of the biggest challenges
for miRNA advancement into the clinic is delivery. Efficient delivery of miRNAs
faces various barriers, such as delivery-associated toxicity, poor transfection,
systemic clearance, poorly understood biodistribution, degradation in circulation,
immune response, and endosomal sequestration [135]. We fully acknowledge that
remarkable strategies for miRNA delivery are being developed to overcome these
obstacles and facilitate miRNA transport. We anticipate that rational design of safe
and efficient new generation miRNA carriers will be instrumental for the clinical
translation of miRNAs. Another challenge that requires further study is the safety
proﬁle of miRNAs. It is expected that the results from the ﬁrst miRNA cancer
treatment in early clinical trials will provide the ultimate answer to that concern;
and yet, preliminary evidence has not shown evidence of negative side e↵ects or
problems with dose tolerance. The history of miRNAs is particularly inspiring in
showing the importance of basic research, which in this case, has proven to be
relevant in the development of new treatments for cancer.
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2. FOLAMIRS: LIGAND-TARGETED, VEHICLE-FREE
MICRORNA REPLACEMENT THERAPY
In accordance with the American Association for the Advancement of Sciences
(AAAs) policy on author use, the following publication (Orellana et al., 2017) is the
accepted version of the article published in the journal Science Translational
Medicine (http://stm.sciencemag.org/content/9/401/eaam9327)

and

has been

reprinted with permission from AAAS. All experiments and procedures were
performed by Esteban A. Orellana unless otherwise noted in the text.

2.1

Summary
The therapeutic potential of microRNA replacement therapies is hindered by

deﬁcient delivery vehicles. Due to the fast degradation of naked miRNAs in vivo,
various delivery strategies rely on encapsulation of the mimics; however, these
strategies often show high toxicity levels in vivo due to non-speciﬁc tissue
distribution. In this work, a mechanism that is able to deliver minimally modiﬁed
miRNA mimics to cancer cells is tested in cell-based experiments and in in vivo
models of human cancer [134]. The method relies on the direct attachment of a
miRNA mimic to a targeting ligand (Folate, FolamiR) whose cell receptor is
overexpressed in cancer cells [134]. The results show that the FolamiR platform is
able to deliver functionally active small RNAs speciﬁcally to cancer cells, causing
downregulation of gene targets, and more importantly slowing down tumor growth.
This method might help reduce unwanted toxicity twofold: 1) by delivering small
RNAs speciﬁcally to tumor tissues and 2) by eliminating the use of toxic vehicles
[134].
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2.2

Introduction
The lack of efficient delivery vehicles is recognized as a major bottleneck in

microRNA (miRNA)-based therapeutics.

Problems such as delivery-associated

toxicity, poor transfection, systemic clearance, poor speciﬁc biodistribution, and
degradation in circulation are hindering the therapeutic potential of miRNAs [178].
These vehicle-related defects may be overcome by eliminating the vehicle using a
targeted vehicle-free delivery approach. Previously, this strategy has been developed
for the delivery of antagomirs (antisense miRNA inhibitors)[82, 44, 54, 110, 29],
which are used to sequester overexpressed miRNAs,

and other antisense

oligonucleotides that inhibit gene expression by hybridization via sequence
complementarity [154, 182]. However, a similar approach has not been successfully
used to reintroduce clinically relevant miRNAs (mimics).
Vehicle-free delivery of antagomirs has advanced more rapidly than delivery of
miRNA mimics due to modiﬁcations that can be made to the backbone of the
antagomirs, which protect the molecule from serum ribonucleases.

While the

backbone of antisense oligonucleotides and antagomirs, such as Miravirsen, can be
modiﬁed to protect RNAs from degradation in circulation [54, 72, 85, 142, 119, 124],
miRNA mimics are not amendable to major stabilizing modiﬁcations since the
alterations prevent recognition and loading into Argonaute[11, 37], which is essential
for miRNA function.

Therefore, generating a functional miRNA mimic that is

completely resistant to endonucleases is not realistic.

In light of this, miRNA

mimics have been packaged into various protective delivery vehicles including
nanoparticles[193, 63, 28, 30], liposomes[45], micelles[121], and hydrogels[36].
Our previous work demonstrated that lentiviral- and liposomal-mediated
delivery of the tumor suppressive miRNA, miR-34a reduces tumor burden in various
non-small cell lung cancer (NSCLC) mouse models[77, 76]. In addition to vehicleand

viral-mediated

miRNA

delivery,

oligonucleotides have also been tested.

systemic

injection

of

vehicle-free

However, this approach has proven
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problematic due to the pharmacokinetic and stability limitations associated with
intravenous delivery and thus rely either on local delivery, or necessitate achieving a
high oligonucleotide concentration that is often only seen in kidneys and liver[154].
While local delivery is an option, achieving delivery beyond sites that are accessible
to local delivery, such as to micrometastatic lesions, is not achievable.
To overcome the challenge of non-targeted delivery, cell surface receptors
speciﬁcally overexpressed on tumor cells can be exploited to further enhance
miRNA mimic delivery beyond sites accessible by local delivery. If the ligands that
bind to those receptors are engineered to carry a functionally active miRNA, the
resulting molecule could potentially be used to target miRNAs speciﬁcally to tumor
cells[161]. To be useful, the target receptor must meet two criteria: the receptor
must be overexpressed on the cancer cell relative to normal cells, and the expression
level of the receptor must be sufficient to enable delivery of therapeutic quantities of
a miRNA to the cancer cell. An attractive candidate that fulﬁlls both of these
criteria is the folate receptor (FR), which is overexpressed on many epithelial
cancers, including cancers of the breast[200], lung[16], ovary[75], kidney[136], and
colon[191] and various hematological malignancies such as acute myeloid
leukemia[108]. However, the presence of the FR on normal tissues appears to be
limited in quantity, inconsequential for targeted drug applications, or inaccessible to
blood-borne folates[161]. Fortunately, the FR has a suitable ligand, Vitamin B9
(folic acid), that binds to the FR with high binding affinity, is selective for the FR,
and contains a derivatizable functional group for facile conjugation to imaging or
therapeutic agents that does not interfere with binding to the receptor[172]. Thus,
FR/folate-conjugate therapy has great potential for delivery of small RNAs such as
miRNA or siRNA[169, 199].
Successful folate-targeted delivery,

with payloads as diverse as small

radiopharmaceutical agents to large DNA-containing formulations, has been
exempliﬁed both at the preclinical and clinical levels[88]. However, folate-mediated
delivery of small RNAs lags behind due to the hypothesis that RNAs in circulation
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need to be protected. To achieve this level of protection, various strategies pursued
in the ﬁeld of small RNA delivery have incorporated folate onto a carrier vehicle
(dendrimer, copolymer, liposome)[74, 179]. These complexes have a very large size,
which often leads to hampered penetration of target tissues due to the dense
extracellular matrix found in most solid tumors[177].
Herein, we provide evidence for a unique strategy that directly links miRNA
mimics to the folate ligand, which we have termed FolamiRs (Figure 2.1A,B). The
rationale is that these smaller FolamiRs perfuse solid tumors more easily than larger
miRNA encapsulating vehicles. One major concern with this approach is that the
native form of small RNAs is relatively unstable in blood[182].

In an e↵ort to

overcome this potential issue, yet retain activity of the mature strand, the passenger
strand of the miRNA mimic is minimally modiﬁed with 20 -O-methyl RNA bases,
which stabilizes the RNA and increases nuclease resistance without impairing
Argonaute loading[1]. Furthermore, in our previous studies, it was shown that folate
linked to rhodamine saturates a solid tumor after i.v. injection in less than ﬁve
minutes[177, 190, 189]. The speed by which the folate-conjugated molecules enter
the tumor demonstrates that FolamiRs need only to survive in circulation for a very
short period of time.
We present evidence for a method to deliver functional and virtually unprotected
miRNAs speciﬁcally and rapidly to tumor tissue. We show that miRNA-34a (miR34a) is selectively targeted to the tumor, enters the tumorigenic cells, downregulates
target genes, and suppress growth of tumors in vivo. Success is dependent on fast
tumor uptake that is mediated by directly conjugating miR-34a to folate (FolamiR34a).
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Fig. 2.1. Speciﬁcity of FolamiR uptake in cells in culture. A) Proposed
mechanism of action of FolamiRs. B) Structures of FolamiR-34a
conjugates bearing an unreleasable ligand FolamiR-34a, a releasable
ligand FolamiR-SS-34a (disulﬁde bond shown in red), and a miR-34a
conjugate bearing an unreleasable folate ligand and a NIR moiety
(shown in green) NIR-FolamiR-34a. Folate moiety is shown in
blue and miRNA in red. C) Identiﬁcation of folate receptor ↵
(FR↵) in FR+ MB-231 breast cancer cells and in FR- A549 lung
cancer cells. Histograms represent overlaid ﬂow cytometry data as
a percentage of unstained, FR↵, and isotype control stained cells.
D) NIR-FolamiR-34a uptake in FR+ MB-231 cells compared to FRA549 cells. Histograms represent overlaid ﬂow cytometry data as a
percentage of unstained, and NIR-FolamiR-34a (50nM) stained cells.
E) Folate-ﬂuorescein isothiocyanate (Fol-FITC) uptake in FR+ MB231 cells compared to FR- A549 cells. Scale bar: 50 um. F) Targeted
silencing of miR-34a Renilla sensor using FolamiR in vitro. Data
points were normalized to FolamiR-NC (negative control: scrambled
miRNA) for each time point. Error bars: mean ± s.d. Each
experiment corresponds to n=3, 4 technical replicates per treatment,
statistical analysis performed with a one-way ANOVA and Bonferroni
correction, (**, P < 0.01). From Orellana et al. (2017). Reprinted
with permission from AAAS.
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2.3

Materials and Methods

2.3.1

Materials

Materials described in Orellana et al.(2017) [134].

Amino acids for peptide

synthesis were purchased from Aapptec, USA. N - Hydroxybenzotriazole (HOBt)
and

benzotriazol-1-yloxytris(pyrrolidino)phosphonium

hexaﬂuorophosphate)

(PyBOP) were obtained from Sigma-Aldrich and Chem-Impex Int. (Chicago, IL)
respectively. Solid phase peptide synthesis (SPPS) was performed using a standard
peptide synthesis apparatus (Chemglass, Vineland, NJ) by following standard
Fmoc-solid phase peptide synthesis procedure [105]. Unless otherwise speciﬁed, all
other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). All folate and
folate-NIR dye conjugates were puriﬁed by preparative reverse phase (RP)-HPLC
(Agilent) and LC/MS analyses were obtained using an Agilent mass spectrometer
coupled with a UV diode array detector.

2.3.2

Synthesis procedure for Folate-DBCO/ Folate-SS-DBCO

Synthesis was performed by Logantahan Rangasamy or Srinivasarao Tenneti as
described in Orellana et al.(2017) [134].

Brieﬂy, folate-ethylenediamine (EDA)

peptide was prepared by following standard Fmoc-solid phase peptide synthesis
procedure [173]. Folate containing free amine group was cleaved from the resin and
puriﬁed by reverse phase (RP) high performance liquid chromatography (HPLC).
Next, puriﬁed Folate-EDA peptide (0.0100 g, 0.0206 mmol, 1 eq.) was mixed with
Dibenzocyclooctyne - N - hydroxysuccinimidyl ester (NHS-DBCO, 0.0091 g, 0.0227
mmol, 1.1 eq.)

or Dibenzocyclooctyne - S - S - N - hydroxysuccinimidyl ester

(NHS-SS-DBCO, 0.0128 g, 0.0227 mmol, 1.1 eq.) in Dimethyl sulfoxide (DMSO)
followed by addition of N,N-Diisopropylethylamine (DIPEA, 0.0039 g, 0.0309 mmol,
1.5 eq.). The reaction mixture was incubated at room temperature for 2 h with
stirring. Progress of the reaction was monitored by liquid chromatography mass
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spectrometry

(LC-MS).

After

complete

conversion

of

Folate-DBCO

or

Folate-SS-DBCO, the crude reaction mixture was puriﬁed by RP-HPLC.

2.3.3

Synthesis

procedure

for

Folate-DBCO-NIR

or

Folate-SS-DBCO-NIR conjugate
Synthesis was performed by Logantahan Rangasamy or Srinivasarao Tenneti as
described in Orellana et al.(2017) [134]. Folate-cysteine (Cys) peptide was prepared
by following manual Fmoc-solid phase peptide synthesis procedure [173]. Folate
containing free amine and sulfhydryl group was then cleaved from the resin and
puriﬁed by RP-HPLC at pH 5.0. Puriﬁed Folate-Cys peptide (0.0100 g, 0.0151
mmol, 1. eq.) was added to Maleimide-NIR Dye (0.0190 g, 0.0167 mmol, 1.1 eq.) in
DMSO followed by addition of DIPEA (0.0029 g, 0.0227 mmol, 1.5 eq.).

The

reaction mixture was incubated at room temperature with stirring and then the
crude reaction mixture was puriﬁed by RP-HPLC. Folate-Cys-NIR peptide (0.0050
g, 0.0027 mmol, 1 eq.) was added to NHS-DBCO (0.0016 g, 0.0041 mmol, 1.5 eq.)
or NHS-SS-DBCO (0.0023 g, 0.0041 mmol, 1.5 eq.) in DMSO followed by addition
of DIPEA (0.0054 g, 0.0041 mmol, 1.5 eq.). The reaction mixture was incubated at
room temperature with stirring. Progress of the reaction was monitored by LC-MS.
After complete conversion of Folate-DBCO-NIR or Folate-SS-DBCO-NIR the crude
reaction mixture was puriﬁed by RP-HPLC.

2.3.4

Preparation of Folate-miRNAs (FolamiRs)

FolamiR preparation was performed as described in Orellana et al.(2017)
[134].MiRNA duplexes were constructed using two RNA oligonucleotides: denoted
as miR-34a-5p guide strand and miR-34a-3p passenger strand (Integrated DNA
Technologies).

The miR-34a-3p passenger strand comprises a 20nt RNA oligo

double modiﬁed with an azide linker on the 50 end and 20 -O-methyl RNA bases on
the 30 end, and the miR-34a-5p guide strand comprises a 22 nt RNA oligo with
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minimal modiﬁcations on the 30 with 20 -O-methyl RNA bases. A scrambled miRNA
(Negative control) synthesized with the same modiﬁcations was used to form a
control duplex. A bi-orthogonal click reaction was performed between Folate-DBCO
and azide modiﬁed antisense miR-34a (or scramble) as shown in Figure 2.2. For
experiments with siLuc2 the oligos with the following sequences were used: sense
strand :

50 GGACGAGGACGAGCACUUCUU 30 and antisense strand:

50

GAAGUGCUCGUCCUCGUCCUU 30 . Click reaction[113] was performed at a 1:10
molar ratio (azide oligo: Folate DBCO) at room temperature in water for eight
hours and then cooled to 4 C for four hours. Unconjugated folate was removed from
the reaction using Oligo Clean and Concentrator (Zymo Research) per manufacturer
instructions.

Conjugation was veriﬁed using 15% tris-base,

acetic acid,

ethylenediaminetetraacetic acid (TAE) native PAGE and MALDI spectral analysis.
For folate-NIR compound conjugation an additional veriﬁcation was done using
Licor Odyssey CLX (Licor).
After conjugation, the miR-34a-5p guide strand was annealed to the folate and
NIR-folate conjugates. Brieﬂy, folate-miR-34a-3p and miR-34a-5p were mixed in an
equal molar ratio (1:1, ﬁnal concentration 5uM each) in annealing bu↵er: 10mM
Tris bu↵er pH 7 (Sigma), supplemented with 50mM NaCl (Sigma), and 1mM EDTA
(Sigma), and incubated at 95 C for ﬁve minutes and then ramp cooled to room
temperature over a period of one hour and then stored at -80 C.

2.3.5

Stability assay in serum

Stability assays were performed as described in Orellana et al.(2017) [134].The
duplex RNA oligonucleotides and the FolamiR conjugates were incubated in 50% fetal
bovine serum (Sigma) in water at 37 C for the indicated times. RNA samples were
collected and analyzed using 15% TAE polyacrylamide gel electrophoresis (PAGE).
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2.3.6

Flow Cytometry

Flow cytometry was performed as described in Orellana et al.(2017) [134]. FR
positive human MDA-MB-231 cells and FR negative human A549 cells grown as
described previously [174] were detached by trypsinization and washed twice in
ice-cold phosphate bu↵ered saline (PBS; pH 7.4) and resuspended to a density of
1x107 cells/mL in serum free medium. Cell viability was determined by trypan blue
exclusion and cells were only used if the viability of cells was >80%. Next, ﬂow
cytometric analyses were performed following standard protocols. Brieﬂy, 1x106
cells were incubated with PE anti-FOLR1 antibody (Cat. 908303, Biolegend) or
matched isotype antibody (Cat. 400213, Biolegend) as a control and analyzed by
ﬂow cytometric analysis using LSR Fortessa ﬂow cytometer (BD Biosciences, San
Jose, CA, USA). Data was analyzed using FlowJo software v10 (Tree Star, Inc, OR,
USA). Functionality of the FR was conﬁrmed ﬁrstly by incubating MDA-MB-231
and A549 cells with FolamiR-34a-NIR (50nM) followed by ﬂow cytometric analyses
as described above, and secondly by microscopy analysis of cells incubated with
folate-ﬂuorescein isothiocyanate (FITC)[174] to a ﬁnal concentration of 50nM. Cells
were evaluated at di↵erent time points using an Olympus IX73 microscope equipped
with a 1.25X objective, Olympus DP80 camera, and CellSens 1.11.

2.3.7

In vitro FolamiR delivery

Experiments were performed as described in Orellana et al.(2017) [134].
MDA-MB-231 triple-negative breast cancer cells (HTB-26, mycoplasma free, tested
for mycoplasma contamination via MycoAlert Mycoplasma Detection Kit - Lonza)
were grown in RPMI 1640 medium, no folic acid (Life Technologies) supplemented
with 10% fetal bovine serum (Sigma), 100 U/mL penicillin and 100 ug/mL
streptomycin (Hyclone, GE Healthcare Life Sciences) and maintained at 37 C in 5%
CO2 . For luciferase reporter experiments, a miR-34a sensor plasmid was generated
by inserting the antisense sequence to miR-34a into the 30 untranslated region of
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Renilla luciferase in the vector (psiCHECK, Promega). MiR-34a speciﬁc silencing
was conﬁrmed in MDA-MB-231 cells by transiently transfecting a miR-34a sensor or
a mutated miR-34a sensor. MiR-34a sensor expressing cells were transfected with a
miR-34a mimic using Lipofectamine RNAimax (Life Technologies) to conﬁrm
silencing mediated by exogenous miRNA. To generate stable clones, MDA-MB-231
cells were seeded in six-well plates at a density of 1x106 cells/well and were
transfected with 2 ug of miR-34a sensor plasmid using Lipofectamine 2000 (Life
Technologies).

Stable clones were selected using Hygromycin B (500 ug/mL;

Hyclone, GE Healthcare Life Sciences) as a selection marker. Single clones were
evaluated for Renilla expression and the clone with the highest Renilla expression
was selected.

MB-231 sensor cells were seeded into 96-well plates containing

FolamiR-34a, Fol-SS-34a and FolamiR-NC (negative control) in folic acid and serum
free RPMI medium for a ﬁnal concentration of 50 nM. Untreated and unconjugated
duplex miRNA were included as controls. Renilla luciferase values were obtained 24,
48, 72, 96 and 120h post incubation using the Renilla Glo Luciferase kit (Promega)
following the manufacturer instructions.

Renilla levels were normalized to

FolamiR-NC for each time point. Experiments were performed three times with
technical triplicates for each condition.

2.3.8

Cell proliferation assays

Cell proliferation assays were performed as described in Orellana et al.(2017) [134].
Sulforhodamine B (SRB, Sigma) assay was used as a proxy for cell proliferation in
96-well plates [131]. Brieﬂy, following FolamiR treatment cells were ﬁxed with 10%
tricholoroacetic acid in complete media and stained for 1 hour with 0.4% (wt/vol)
SRB in 1% acetic acid. Unbound dye was removed by four washes with 1% acetic
acid. Finally, protein-bound dye was extracted with 10mm unbu↵ered Tris base
and absorbance at 510nm was obtained using a GloMax Multi+ spectrophotometer
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(Promega). Absorbance values (proxy for cell mass) were normalized to that of cells
cultured in the presence of FolamiR-NC for each time point.

2.3.9

Flank tumor establishment

Tumor implantations were performed as described in Orellana et al.(2017) [134].
Brieﬂy, for single-dose studies, subcutaneous tumors were induced in female Nu/Nu
F oxn1nu ; Charles River) congenic mice (6 weeks, n= 5) by subcutaneous

(N U

injection of 5x106 MDA-MB-231 sensor cells suspended in 200uL of Matrigel
(Corning). For longitudinal studies, parental MDA-MB-231 cells were used. To
determine tumor growth, individual tumors were measured using a vernier caliper
and tumor volume was calculated by: tumor volume (mm3 ) = width x (length2 ) x
2 1 . Animals were excluded if tumors had not reached a volume of 150 cm3 by the
time of treatment. For single dose experiments, animals were injected intravenously
(i.v.)

with 5 nmol of FolamiRs after acquisition of luminescent and ﬂorescence

signals.

For multiple dosing experiments, animals were randomized into

experimental arms by minimizing the di↵erences in their mean tumor size. When
tumor volume reached ⇠200mm3 animals were treated with i.v. injections of 1 nmol
FolamiR every three days. All experimental protocols were approved by the Purdue
Animal Care and Use Committee and were in compliance with NIH guidelines for
animal use.

2.3.10

Bioluminescent and infrared imaging

In vivo imaging was performed as described in Orellana et al.(2017) [134].
RediJect

Coelenterazine

h

Bioluminescent

Substrate

(PerkinElmer)

was

administered per the manufacturer’s protocol for in vivo monitoring of tumor
bioluminescence using IVIS Lumina II (Caliper) or Spectral AMI (Spectral
Instruments). Luminescent values were acquired at multiple points after injection of
substrate starting at 20 minutes and only maximal mean radiance values were
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reported. Infrared imaging was conducted using IVIS Lumina II (Caliper) at 745
nm excitation and ICG emission ﬁlters. Non-invasive longitudinal monitoring of
tumor luminescence and ﬂuorescence was conducted by whole-animal imaging
performed at the following time points: 0, 24, 48, and 72h (n= 3 animals per
experimental group). Gross organ images were acquired using the 800 nm channel
in the Licor Odyssey CLX (Licor).

2.3.11

Maximum Tolerated Dose (MTD) study

MTD studies were conducted by the Biological Evaluation Core at Purdue
University as described in Orellana et al.(2017) [134]. Balb/c mice (8 weeks of age)
were administered one intravenous injection of 33.3, 10 or 1 nmol of FolamiR-34a.
Animals were observed post administration for 2 weeks. The mice were observed for
changes in body weight and clinical observations (rapid weight loss, diarrhea, rough
hair coat, hunched posture, lethargy, labor breathing, neurological signs, etc.). The
mice were allowed ad libitum feed and water. A necropsy was performed at the end
of the study.

Whole blood, serum, and organ tissue were collected for further

analysis.

2.3.12

Induction of tumor formation in Kras;p53 mice

Tumor induction was performed as described in Orellana et al.(2017)
[134].Induction of tumor formation in KrasLSL

G12D/+

; T rp53f lx/f lx (FVB.129

background) double mutant mice (6 to 10 weeks old) was performed based on the
method of DuPage et al.[42]. Brieﬂy, lung speciﬁc transgene activation was achieved
via intratracheal delivery of Adenoviral particles (106 PFU) encoding for Cre
recombinase. Tumors were allowed to preform for eight weeks prior to experiments.
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2.3.13

Tumor progression monitoring using Magnetic Resonance Imaging
(MRI)

Tumor monitoring was conducted as described in Orellana et al.(2017) [134]. MRI
scans of induced and non-induced animals (scans of healthy tissue) were obtained
using a 7.0 Tesla Bruker Biospec 70/30 USR Scanner (Billerica, MA) and a 40 mm
mouse volume coil at the Purdue MRI Facility. Animals were anesthetized using a
2.5% v/v isoﬂurane in O2 for 5 minutes and then moved to the heated animal bed
where anesthesia was set to 2%. Respiration rate was monitored via pressure sensor.
A low-resolution multiplane scout scan was obtained using the following parameters:
TR= 4s, TE= 1.5 ms, FOV= 30 x 30 mm2 , slice thickness= 1 mm, data matrix= 256
x 256, 7 slices per plane (axial, coronal and sagittal), approximate time of scan per
mice= 1 minute. The scout scan was used to align the spine of the mouse to collect
high-resolution images of the lungs using the following parameters: TR= 4s, TE=
1.5 ms, FOV= 30 x 30 mm2 , slice thickness= 0.5 mm, data matrix= 256 x 256, 30
slices per plane (axial and coronal), approximate time of scan per mice= 5 minutes.
Quantiﬁcation of tumor burden was conducted following the manual segmentation
protocol described by Krupnick et al.[81]. This analysis of tumor burden by MRI
takes advantage of the vast di↵erence in MR image intensities between tumor tissue
(bright) and normal lung tissue (dark) and uses the average lung image intensity
as a proxy for tumor burden[81]. Brieﬂy, lung MR images are manually segmented
using ImageJ 2.0.0 and the average lung image intensity normalized to that of the
liver within the same animal is calculated. To determine tumor progression within
an animal the average lung image intensity is then normalized to the ﬁrst day of
treatment. Furthermore, tumor and whole lung volumes per animal were calculated
using three-dimensional reconstruction using ITK-Snap and Paraview 5.2 software
(Kitware, NY, USA)[170]. Tumor/whole lung ratios were obtained at the indicated
times showing the percentage of lung volume occupied by tumors.
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2.3.14

Folate uptake studies in Kras;p53 mice

Folate uptake studies were conducted as described in Orellana et al.(2017) [134].
For folate uptake studies, 5 nmoles of OTL38 (kindly provided by On Target
Laboratories, LLC, West Lafayette, IN), a ﬂuorescent imaging conjugate composed
of folate tethered to a ﬂuorescent near infrared (NIR) dye currently in clinical trials
(Clinical trial identiﬁer: NCT02769533)[172, 78, 128], were delivered systemically
through the tail vein into healthy and tumor bearing mice (n= 3; 8 weeks post
transgene activation). Twenty-four hours after the injection animals were sacriﬁced
and perfused with saline. Whole organ images were acquired using the 800 nm
channel in the Licor Odyssey CLX (Licor).

Lungs were ﬁxed in 10% bu↵ered

formalin and paraffin embedded according to standard procedures. Sections were
stained by hematoxylin and eosin (H&E) and evaluated using an Olympus IX73
microscope equipped with a 1.25X objective, Olympus DP80 camera, and CellSens
1.11. Tumor burden was calculated using ImageJ 2.0.0, which represents the tumor
area relative to the total lung area obtained from three independent sections for
each animal. Unstained mounted sections were evaluated in the 800 nm channel in
the Licor Odyssey CLX (Licor) and using an Nikon TiS microscope equipped with a
20X objective, an ICG band pass ﬁlter (Ex: 780-800; Ex: 810-860; Semrock,
Brightline), a xenon/mercury light source (Nikon, Japan), Photometrics QuantEM
EMCCD camera, and NIS-Elements (Nikon, Japan).

2.3.15

FolamiR treatment in Kras;p53 mice

FolamiR treatment was performed as described in Orellana et al.(2017) [134].
For multiple dosing experiments with FolamiR-34a, tumor-bearing animals (8 weeks)
were randomized into experimental arms by minimizing the di↵erences in their MRI
measured tumor burden. Animals were treated with i.v. injections of 1 nmol FolamiR
every three days (10 injections total) and tumor progression was monitored using a
7.0 Tesla Bruker Biospec 70/30 USR Scanner (Billerica, MA) as described above
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every week for four weeks. Twenty-four hours after the ﬁnal injection animals were
sacriﬁced and perfused with saline. Lungs were harvested, ﬁxed in 10% bu↵ered
formalin and paraffin embedded according to standard procedures. Sections were
stained by hematoxylin and eosin (H&E) and evaluated as described earlier. Mice
were maintained on a folic acid deﬁcient diet (Envigo, TD.95247) starting at six weeks
after tumor induction and during the experiment series.

2.3.16

In vivo blocking of FR

In vivo blocking of FR was conducted as described in Orellana et al.(2017) [134].
Subcutaneous tumors were induced in female Nu/Nu (N U

F oxn1nu ; Charles

River) congenic mice (6 weeks, n= 3) following injection of 5x106 FR positive
human MDA-MB-231 sensor cells (right side) and FR negative human A549 cells
(left side) suspended in 200uL of Matrigel (Corning). Tumors were allowed to form
and mice bearing A549 and MDA-MB-231 tumors of similar size were included in
the experiment. For the Kras;p53 mouse model, tumors were allowed to form for
eight weeks after transgene activation (n= 3). Tumor formation was monitored
using

MRI.

Competition

studies

were

performed

in

mice

(n=

3)

by

co-administration, via the tail vein, of 5 nmoles of FolamiR-34a-NIR for the
xenograft model or 5 nmoles of OTL38 for the Kras;p53 mouse model in the
presence or absence of 500 nmoles ( 100-fold molar excess) of folic acid
glucosamine. Folic acid glucosamine conjugate was used because of its increased
solubility at low pH compared folic acid and to prevent precipitation in the kidneys
[196]. In vivo whole animal imaging and ex vivo tissue distribution studies were
performed as described above.
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2.3.17

RNA isolation and miRNA expression analyses using quantitative
PCR

RNA isolation and expression analyses were conducted as described in Orellana
et al.(2017) [134]. MDA-MB-231 derived tumors from Nu/Nu mice (N U

F oxn1nu ;

Charles River) were collected in RNA Later (Life Technologies) and stored at -80 C.
Tumor tissues (50 mg) were placed in 2 mL collection tubes containing 700 uL QIAzol
lysis reagent (Qiagen) and 1.4 mm ceramic beads. Samples were disrupted using a
bead mill (Fisher Scientiﬁc) at 4 m s

1

for 3 minutes. Total RNA was extracted

using RNeasy Mini Kit (Qiagen) according to the manufacturer instructions. Next,
cDNA was generated using miScript II RT Kit(Qiagen) and miScript HiFlex Bu↵er
using 1 ug of total RNA. For miR-34a standard generation, miR-34a mimic (Life
Technologies) was used for cDNA synthesis. qRT-PCR was performed with miRNA
primer assays (Qiagen). The reactions were processed using a QuantStudio 6 Flex
Real-time PCR machine (Life Technologies) using miScript SYBR Green PCR Kit
(Qiagen) under the following cycling steps: 15min at 95 C; 40 cycles at 95 C for 15s,
55 C for 30s, 70 C for 30s; melting curve from 95 C to 60 C at 1.6 C s 1 . Three
technical repeats for each biological replicate (at least 3) were carried out. MiR-34a
copy number was determined using a standard curve covering 1x108 copies to 1x103
copies of miR-34a.

2.3.18

Measurement of Serum cytokines

Experiments were conducted as described in Orellana et al.(2017) [134]. Serum
samples were used to test for IL-6,

and tumor necrosis factor (TNF↵)

concentrations using the mouse speciﬁc cytokine Multi-Analyte ELISArray Kit
(Qiagen) according to manufacturer’s instructions.

Brieﬂy, serum samples were

thawed in ice and cleared from debris by centrifugation at 1000x g at 4 C for 10min
before the analysis. All samples or standards were added to a 96-well plate together
with assay bu↵er.

Plates were shaken gently and incubated for 2h at room
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temperature.

Supernatant was removed and wells were washed.

A detection

antibody was added and the plates were incubated for 1h at room temperature.
Plates were rinsed and incubated with Avidin-HRP solution for 30min at room
temperature.

The wells were washed and development solution was added to

acquire data using a GloMax plate reader (Promega).

Absorbance values were

acquired at 450 nm and 570 nm. The 570 nm readings were subtracted from the 450
nm readings.

Cytokine standard curves were used to calculate the cytokine

concentrations in serum samples (pg/mL). The limits of detection were as follows:
IL-6 58.8 pg/mL, and TNF↵ 30.5 pg/mL. LPS treated Nu/Nu mice (NU-Foxn1nu;
Charles River) were used as positive controls. Mice received an intra-peritoneal
injection of 500 ng/kg lipopolysaccharides (LPS, L6529, Sigma) and serum was
collected two hours post injection.

2.3.19

Statistics

Statistical analyses were performed as described in Orellana et al.(2017) [134].
For two-group analysis a two-tailed Student’s t-test was used to examine group
di↵erences.

Two-way or one-way analysis of variance (ANOVA) was used for

multigroup comparison using Prism statistical package (version 7, GraphPad
Software). Error bars represent either mean ± s.d. or mean ± s.e.m. as denoted in
the ﬁgure legends. Statistically signiﬁcant P values are indicated in ﬁgures and/or
legends as ***, P < 0.005; **, P < 0.01; *, P < 0.05.

2.4

Results

2.4.1

Generation of Folate miRNA conjugates (FolamiR)

When conjugating a drug to a ligand, typically a cleavable bridge is desired for
delivery of therapeutic cargo, as release of the unmodiﬁed cytotoxic agent is often
required for maximal drug efficacy[28]. Since no data were available to indicate if the
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conjugated folate would impair miRNA loading into Argonaute, both releasable and
unreleasable chemistries were tested. The 50 end of a modiﬁed passenger strand of
miR-34a (miR-34a-3p) was conjugated to folate-DBCO (see Figure 2.2 and Figure 2.3
for folate-DBCO synthesis and veriﬁcation) either using an unreleasable conformation
(folate-miR-34a-3p: Fol-34a-3p) or using a releasable conformation (folate-SS-miR34a-3p: Fol-SS-34a-3p), which contains a reducible disulﬁde linkage (SS) between the
miRNA and the folate molecule (Figure 2.1B). The mature strand of miR-34a (miR34a-5p) was then annealed to the Fol-34a-3p or Fol-SS-34a-3p conjugates, generating
FolamiR-34a duplexes (FolamiR-34a: unreleasable, and FolamiR-SS-34a: releasable).
Conjugates were identiﬁed following polyacrylamide gel electrophoresis (Figure 2.4)
and matrix-assisted laser desorption/ionization (MALDI) spectral analysis (Figure
2.5). To visualize FolamiR-34a in vivo, a near infrared dye was conjugated to folate
(NIR-Fol). The miR-34a duplex was then conjugated to NIR-Fol or NIR-Fol-SS
(Figures 2.1B, 2.2B,C) and the resulting conjugates were validated (Figures 2.6
2.8).

2.4.2

FolamiR uptake is speciﬁc to cells overexpressing the FR

MDA-MB-231(MB-231) breast cancer cells express detectable levels of FR on
the plasma membrane [116] making this cell line a plausible model for evaluating
FolamiR activity.

To verify expression of the FR ﬂow cytometric analyses was

performed comparing MB-231 cells and A549 cells (FR negative control). MB-231
cells were conﬁrmed to express detectable levels of FR↵ (Figure 2.1C). These results
were corroborated by analyzing the cellular uptake of NIR-FolamiR-34a using ﬂow
cytometry (Figure 2.1D) and folate-ﬂuorescein isothiocyanate (Fol-FITC) conjugate
uptake using ﬂuorescent microscopy (Figure 2.1E). Both folate conjugates were
taken up by the FR positive (FR+) cell line MB-231 but not by the FR negative
(FR-) A549 cell line.

This observation was functionally conﬁrmed following

treatment of MB-231 and A549 cell lines transiently expressing a miR-34a Renilla
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Fig. 2.2. General synthesis procedure of folate conjugates. A)
Synthesis of folate-DBCO and folate-SS-DBCO used for conjugating
miRNAs via bio-orthogonal click reaction. B) Synthesis of folateDBCO-NIR and folate-SS-DBCO-NIR. C) Structure of FolamiR34a-NIR and FolamiR-SS-34a-NIR conjugates. Figure prepared by
Logantahan Rangasamy. From Orellana et al. (2017). Reprinted
with permission from AAAS.

sensor with FolamiRs. The sensor is a Renilla gene followed by a single miR-34a
complementary binding site, allowing for monitoring of the post-transcriptional
regulation of Renilla by miR-34a. The sensor in both cell lines was responsive to
transfected miR-34a mimics (Figure 2.9); however, following FolamiR-34a exposure
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Fig. 2.3. LC-MS spectra of folate conjugates. A) LC-MS of FolateDBCO conjugate. B) LC-MS of Folate-SS-DBCO conjugate. From
Orellana et al. (2017). Figure prepared by Logantahan Rangasamy.
Reprinted with permission from AAAS.

the sensor was only downregulated in MB 231 cells (Figure 2.1F), suggesting that
FolamiR targeting is dependent on FR expressing cells. Taken together these results
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Fig. 2.4. Evaluation of Folate-miRNA conjugation measured by 15%
native TAE PAGE. A) In the table, + indicates the presence of
a particular ligand conjugated to miR-34a-3p. B) Gel red stained
polyacrylamide gel. Each lane was loaded with 200 pmols of
unconjugated oligo or folate-miRNA. PAGE results suggest successful
conjugation as visualized in the mobility shift in conjugated folatemiRNA compounds. The presence of a duplet in lane 3 could suggest
premature reduction of the disulﬁde bond. From Orellana et al.
(2017). Reprinted with permission from AAAS.

suggest that MB-231 is a FR+ cell line and provide preliminary evidence for the
speciﬁc uptake of FolamiR conjugates via FR interaction.

2.4.3

Activity of FolamiRs in cells

To monitor FolamiR-34a activity, MB-231 cells were generated to stably express
the miR-34a Renilla luciferase sensor (MB-231 sensor) or a mutated version of the
sensor that is unresponsive to miR-34a. A single clone with the highest level of
Renilla (Figure 2.10) was used to assess FolamiR-34a activity. When FolamiR-34a
or FolamiR-SS-34a was added to the MB-231 sensor cells (in the absence of
transfection reagent) there was a decrease in Renilla activity 72 hours after exposure
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Fig. 2.5. MALDI spectra of FolamiRs. A) MALDI spectra of
FolamiR-34a conjugate. B) MALDI spectra of FolamiR-SS-34a
conjugate. Figure prepared by Logantahan Rangasamy. From
Orellana et al. (2017). Reprinted with permission from AAAS.

(Figure 2.11A). Renilla activity rebounded 120 hours following exposure, likely due
to replication-induced dilution of FolamiR-34a in the cells or degradation of
FolamiR-34a. Proliferation of MB-231 sensor cells was reduced following a single
FolamiR-34a treatment (Figure 2.11B), which correlated with the reduction in
Renilla activity.

Surprisingly, both the releasable and unreleasable FolamiRs

efficiently entered the cell and retained activity, suggesting that the conjugated
folate does not interfere with loading of miR-34a-5p into Argonaute. To determine if
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Fig. 2.6. LC-MS spectra of folate-NIR conjugates. A) LC-MS
of Folate-DBCO-NIR conjugate. B) LC-MS of Folate-SS-DBCONIR conjugate. Figure prepared by Logantahan Rangasamy. From
Orellana et al. (2017). Reprinted with permission from AAAS.

the sensor in the stable cell line responded to FolamiR-34a in a dose-dependent
manner, MB-231 sensor cells were exposed to increasing concentrations of
FolamiR-34a or control. A dose-dependent reduction in Renilla activity was only
observed in cells treated with FolamiR-34a (Figure 2.11C). To test if cellular uptake
of FolamiRs is dependent on FR expression on the cell membrane, in vitro
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Fig. 2.7. Evaluation of NIR-FolamiR conjugation measured by 15%
native TAE PAGE. A) In the table, + indicates the presence of
a particular ligand conjugated to miR-34a-3p. B) On the left,
Gel red stained polyacrylamide gel. On the right, NIR imaging of
polyacrylamide gel using the 800 nm channel of Licor Odyssey CLX
(Licor). Each lane was loaded with 200 pmols of unconjugated oligo
or folate-miRNA. PAGE results conﬁrmed successful conjugation as
visualized in the mobility shift in lanes 2 and 3. From Orellana et al.
(2017). Reprinted with permission from AAAS.

competition assays were performed. Increasing the amount of folic acid glucosamine
conjugate (folate-glucosamine) resulted in a dose-dependent reduction in cell-speciﬁc
NIR-FolamiR-34a signal,

indicating that folate-glucosamine competes with

NIR-FolamiR-34a (Figure 2.11D). More importantly, folate-glucosamine treatment
abrogated the silencing e↵ect of NIR-FolamiR-34a on the miR-34a Renilla sensor in
a dose-dependent manner (Figure 2.11E). To validate the concept as a delivery
method for other small RNAs, besides miRNAs, an siRNA targeting ﬁreﬂy
luciferase (siLuc2) was conjugated to folate. Fireﬂy luciferase activity of MB-231
cells transiently expressing ﬁreﬂy was reduced following exposure of the cells to
Folate-siLuc2 (Figure 2.12) suggesting that folate mediated delivery can be used to
target other small RNAs to FR+ cells.

Altogether, these results support that
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Fig. 2.8. MALDI spectra of FolamiR-NIR conjugates. A) MALDI
spectra of FolamiR-34a-NIR dye conjugate. B) MALDI spectra of
FolamiR-SS-34a-NIR dye conjugate. Figure prepared by Logantahan
Rangasamy. From Orellana et al. (2017). Reprinted with permission
from AAAS.

FolamiRs can deliver small RNAs that retain their function to cells overexpressing
the FR and that the delivery is dependent on FR expression.
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Fig. 2.9.
miR34a Renilla sensor response to miRNA mimic
transfection. MDA-MB-231 breast cancer cells and A549 lung cancer
cells transiently expressing a miR-34a Renilla sensor were used to
monitor miR-34a delivery and activity. MDA-MB-231 and A549 cells
were transfected with 50 nM of miR-34a mimic using Lipofectamine
RNAimax (Life Technologies) and Renilla signal was measured 96
hours post treatment. From Orellana et al. (2017). Reprinted with
permission from AAAS.

2.4.4

Activity of FolamiRs in vivo, in an immunocompromised xenograft
model of breast cancer

Transitioning miRNA delivery methods from cells in culture to in vivo models
presents with multiple challenges such as the potential for destabilization of the RNA
in circulation due to serum ribonucleases, ine↵ective targeting to the tumor cells
due to confounding factors such as the tumor microenvironment, poor uptake of
the miRNA, and the potential for reduced efficacy due to these collective factors.
To show that FolamiRs can overcome these challenges, ﬁrstly, a single 4 mg/kg (5
nmol) dose of each NIR-Fol tagged miRNA (NIR-FolamiR) was delivered via tail
vein injection into animals with palpable MB-231 sensor cell xenografts. Fluorescent
distribution and luciferase activity was measured to monitor targeting speciﬁcity, and
as a surrogate for uptake and intercellular target repression, respectively. Twentyfour hours after injection, NIR-FolamiR was primarily retained in tumor tissues,
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Fig. 2.10. Evaluation of MDA-MB-231 miR-34a sensor cells. A)
Speciﬁcity of the miRNA sensor was monitored by transiently
expressing the miR-34a sensor or a mutated sensor along with a
miR-34a mimic or a negative control (scrambled RNA) in MDA-MB231 breast cancer cells. Cells (1x104 ) were seeded in 96-well plates
and co-transfected with 25ng of plasmid and 6nM of miRNA mimic
using Lipofectamine 2000 (Life Technologies). Renilla activity was
measured 48 hours post transfection using the Renilla Glo Luciferase
kit (Promega). Error bars represent the mean ± s.d., experiments
were performed in triplicate. B) Selection of MB-231 clones based on
Renilla activity. Renilla readings were performed using 1x104 cells
per clone and Renilla levels were measured using the Renilla Glo
Luciferase kit (Promega). From Orellana et al. (2017). Reprinted
with permission from AAAS.

and importantly, cleared from the rest of the organism (Figure 2.13A, left-NIR),
including the liver (Figure 2.13C, Lv). However, only the unreleasable NIR-FolamiR34a induced Renilla knockdown in vivo (Figure 2.13A, right-luciferase, quantiﬁed in
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Fig. 2.11. Cellular response to FolamiRs. A) Targeted silencing of
miR-34a Renilla sensor using FolamiRs in vitro. Data points were
normalized to FolamiR-NC (negative control: scrambled miRNA)
for each time point. B) Proliferation and survival of MB-231
cancer cells as a function of FolamiR treatment (50nM). Data
points were normalized to FolamiR-NC for each time point. Error
bars: mean ± s.d. Each experiment corresponds to n=3 and
3 technical replicates per treatment. C) Dose response of MB231 to FolamiR-34a. Renilla values were measured 96 hours post
treatment. Data points were normalized to FolamiR-NC. Error
bars: mean ± s.d. Each experiment corresponds to n=3 with at
least 4 technical replicates per treatment, D) Displacement of NIRFolamiR-34a binding from MB-231 cells (50 nM, 4 C) with increasing
concentrations of folate glucosamine conjugate. Histograms represent
overlaid ﬂow cytometry data as a percentage of unstained, and NIRFolamiR-34a stained cells. E) In vitro FolamiR-34a competition
assay. MiR-34a Renilla sensor response to FolamiR-34a (50nM,
96 hours) in the presence of increasing concentrations of folate
glucosamine conjugate. Data points were normalized to FolamiRNC (negative control: scrambled miRNA) for each experimental
condition. Experiment corresponds to n=3 and 3 technical replicates
per treatment. Statistical analysis performed with a one-way ANOVA
with post hoc Bonferroni correction, (**, P < 0.01; ****, P < 0.0001).
From Orellana et al. (2017). Reprinted with permission from AAAS.

47

48

Fig. 2.12. Folate mediated delivery of functional siLuc2. A) Fireﬂy
luciferase expression in MDA-MB- 231 expressing a pmiRGlo plasmid
(Promega) respond with ﬁrely luciferase (Luc2) signal modulation
after transfection with an siRNA against Luc2 suggesting that the
ﬁreﬂy signal can be used to monitor siLuc2 uptake and activity. B)
Fireﬂy luciferase signal in MDA-MB-231 cells following treatment
with folate-siLuc2 or Folate-NC (72 hours post treatment, 50 nM
ﬁnal concentration). Untreated and unconjugated duplex siRNA
were also included as controls. MDA-MB-231 were transfected with
50nM of siLuc2 using Lipofectamine RNAimax (Life Technologies)
and Fireﬂy signal was measured 72 hours post treatment. Fireﬂy
activity levels from MDA-MB-231 cells normalized to negative control.
Experiments were performed three times with technical triplicates
for each condition. One-way analysis of variance (ANOVA) and
Bonferroni post hoc test were used to test for statistical signiﬁcance.
Mean ± S.D., ** P<0.01. From Orellana et al. (2017). Reprinted
with permission from AAAS.

2.13B). Importantly, after only a single injection of NIR-FolamiR-34a, Renilla levels
were reduced by approximately 50%, which was greater than the reduction observed
in the cell culture experiments ( Figure 2.11A,C,E). Approximately 3.5x106 copies
of miR-34a per nanogram of total RNA were present in the tumors harvested from
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mice treated with NIR-FolamiR-34a (Figure 2.13D). In contrast, the copy number of
miR-34a in the tumors harvested from mice treated with NIR-FolamiR-SS-34a was
similar to the negative control animals, suggesting that the releasable folate-conjugate
may be degraded or prematurely reduced in circulation. To address this possibility,
FolamiR conjugates were exposed to 50% serum. FolamiR-SS-34a was highly unstable
in the presence of serum while FolamiR-34a remained intact for more than six hours
(Figure 2.14). In fact, FolamiR-34a was more stable than unconjugated miR-34a,
suggesting that folate protects the miRNA from serum nucleases. To determine if
the FolamiRs bind speciﬁcally to FR in vivo, 4 mg/kg (5 nmol) of NIR-FolamiR34a was injected intravenously in the presence or absence of 100-fold molar excess
of folate-glucosamine in nude mice bearing FR+ MB-231 sensor cells engrafted on
the right shoulder and FR- A549 cells engrafted on the left shoulder. The results
indicate that only FR+ MB-231 tumors accumulate the FolamiR conjugate (Figure
2.13E,F), and that this FR dependent accumulation can be blocked by an excess of
folate-glucosamine (Figure 2.13E,F).
Next, a multiple-dosing study was performed to evaluate the efficacy of FolamiR34a. MB-231 xenograft animals were treated with reduced doses of FolamiR-NC or
FolamiR-34a (0.08, 0.4 and 0.8 mg/kg) every three days for a total of seven doses.
Tumors in animals administered the control folate-conjugate grew approximately 3.5fold, while tumor size in animals treated with FolamiR-34a increased modestly (⇠1.5
fold) during the 20-day dosing period (Figure 2.13G and 2.15). Doses as low as
0.08 mg/kg (0.1 nmol) produced a striking and highly signiﬁcant reduction in tumor
growth. Copy number of miR-34a in the excised tumor tissue was approximately 1.5
fold higher than in the tumors extracted from mice administered the control (Figure
2.16). Importantly, there was no evidence of whole organ toxicity or elevation in the
serum cytokines IL-6 or TNF↵ in animals treated with FolamiR-34a (Figure 2.17A).
These results are supported by a maximum tolerated dose (MTD) study performed in
immunocompetent mice in which none of the mice dosed with FolamiR-34a presented
with pathological signs of toxicity or signiﬁcant changes in body weight up to the
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Fig. 2.13. FolamiR-34a inhibits the growth of MB-231 tumors. A)
Representative live imaging of female Nu/Nu congenic mice implanted
with MB-231 sensor xenografts following intravenous injection of 4
mg/kg (5 nmol) of NIR-FolamiR-34a, NIR-FolamiR-SS-34a, or NIRFolamiR-NC. Left side: ﬂuorescent distribution, right side: miR-34a
Renilla sensor signal. B) E↵ects of NIR-FolamiR-34a delivery on miR34a Renilla sensor activity; data normalized to Renilla signal at day 0
(error bars: mean ± s.e.m., n=3).C) Gross images of MB-231 tumors
(T) and whole body organs (Int, intestines; S, spleen; K, kidneys; Lv,
liver; HLu, heart lung) visualized for ﬂuorescence. D) miR-34a levels
from excised MB-231 tumors measured by qRT-PCR at 72 hours post
injection with NIR-FolamiR conjugates (n = 3; error bars: mean ±
s.d). E ) NIR epiﬂuorescence quantiﬁcation from live animals. Nude
mice were implanted with A549 cells on the left shoulder and MB-231
cells on the right shoulder and live imaging was conducted following
intravenous injection of 4 mg/kg (5 nmol) of NIR-FolamiR-34a in
the presence (right) or absence (left) of 100-fold molar excess of
folate-glucosamine (n = 3, error bars: mean ± s.d.). F) Fluorescent
distribution of procured organs and tumors from (E) are shown: A549:
FR- tumor; MB-231: FR+ tumor. G) Tumor size following FolamiR34a treatment (n = 5, error bars: mean ± s.e.m.). Arrows represent
treatment times (0.8 mg/kg:1 nmol intravenous injection). Statistical
analysis performed with a one-way (D, E) or two-way (B, G) ANOVA
with Bonferroni correction, **, P < 0.01; ***, P < 0.001; ****, P <
0.0001. From Orellana et al. (2017). Reprinted with permission from
AAAS.
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Fig. 2.14. Serum stability of FolamiRs in serum. Stability of FolamiRs
and duplex RNA oligos measured by 15% TAE native PAGE after
incubation in 50% serum solution for di↵erent periods of time. A)
Gel red stained polyacrylamide gel following resolution of miRNAs
after serum exposure. B) NIR imaging of polyacrylamide gel using
the 800 nm channel of Licor Odyssey CLX (Licor). From Orellana et
al. (2017). Reprinted with permission from AAAS.

maximum dose tested of 26.64 mg/kg (33.3 nmol) (Figure 2.17B) indicating an MTD
> 26.64 mg/kg.

2.4.5

FolamiR e�cacy in an immunocompetent aggressive Kras;p53 nonsmall cell lung cancer mouse model

We speculated that the FolamiR strategy could be used to deliver miRNA
mimics into other cancer models, importantly, in models with tumors growing in
anatomically correct locations in the presence of an intact immune system. For that
purpose, the aggressive KrasLSL

G12D/+

; T rp53f lx/f lx non-small cell lung cancer

(NSCLC) mouse model was tested for uptake and response to FolamiR-34a. The
KrasLSL
disease

G12D/+

; T rp53f lx/f lx model accurately recapitulates not only NSCLC

progression,

but

also

response

and

resistance

to

conventional

therapies([158, 42, 188]), and has previously been shown to be responsive to
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Fig. 2.15. Tumor growth response to increasing doses of FolamiR34a.
Tumor size following FolamiR-34a treatment (n = 5, error bars
represent mean ± s.e.m., statistical analysis performed with a twoway ANOVA, ***, P < 0.001). Arrows represent treatment times
(intravenous injection). Tumors were measured with a vernier
caliper and tumor volume was calculated by: volume (mm3 ) =
widthx(length2 )x2 1 . From Orellana et al. (2017). Reprinted with
permission from AAAS.

miR-34a replacement therapies([77, 76]), supporting its use as a model for FolamiR
efficacy. Because this model had not yet been validated for FR expression, ﬁrstly,
pulmonary adenocarcinomas of this model were evaluated for folate receptor
expression, and tumor-speciﬁc uptake and retention of folate conjugates. Tumor
bearing animals were intravenously administered OTL38, a clinical version of folate
conjugated to a NIR dye, which is currently undergoing phase II clinical trial for
image-guided surgical resection (NCT02317705) [172, 78, 128]. The folate conjugate
was preferentially retained in lung tumors and cleared from normal healthy tissues
as observed at the gross organ level (Figure 2.18A) and at the histological level
(Figure 2.18B). Importantly, even in tumor-bearing mice, non-tumorigenic tissue
was not targeted; however, small lesions and hyperplastic regions were positive,
highlighting the speciﬁcity of folate conjugates.

Higher magniﬁcation images
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Fig. 2.16. miR34a copy number in tumors treated with FolamiR. MiR34a levels measured by qRT-PCR from (A) breast cancer xenografted
tumors (B) and lung adenocarcinoma KrasLSL G12D/+ ; T rp53f lx/f lx
tumors at 24 hours post last injection (n = 5; error bars represent
mean ± s.d, statistical analysis performed with one-way ANOVA or
Students t-test, **, P < 0.01). From Orellana et al. (2017). Reprinted
with permission from AAAS.

indicate that the near infrared signal is not an artifact of the cell density di↵erences
between healthy and malignant tissues; deﬁned punctate signaling is observed in
tumors following OTL38 administration, as has previously been observed due to
receptor-mediated endocytosis of OTL38 (see insets in Figure 2.18B). To determine
if OTL38 retention in pulmonary adenocarcinomas is mediated by its interaction
with FR an in vivo blockade assay was performed. OTL38 (5 nmol) was injected
intravenously

in

the

presence

or

absence

of

100-fold

molar

excess

of

folate-glucosamine in mice bearing lung tumors. OTL38 retention in lung tumors
was reduced by an excess of folate-glucosamine (Figure 2.18C,D) suggesting that
OTL38 accumulation in tumors is dependent on the FR. These data conﬁrm that
the KrasLSL

G12D/+

; T rp53f lx/f lx tumors speciﬁcally take up and retain OTL38,

suggesting that FolamiR-34a should likewise accumulate in the tumor tissue.
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Fig. 2.17. Serum cytokines and Maximum Tolerated Dose Study.
A) Serum obtained from FolamiR treated Nu/Nu mice bearing
MDA-MB-231 tumors was evaluated for relevant cytokines: tumor
necrosis factor (TNF) ↵, and interleukin (IL)-6 (n=5). Serum from
lipopolysaccharides (LPS) treated mice was included as a positive
detection control (n=2; statistical analysis was performed with a
one-way ANOVA with post hoc Bonferroni correction). B) Body
weight before and after intravenous administration of increasing doses
of FolamiR-34a. Statistical analysis was performed with a two-way
ANOVA with post hoc Bonferroni correction. From Orellana et al.
(2017). Reprinted with permission from AAAS.

To determine if the KrasLSL

G12D/+

; T rp53f lx/f lx tumors are responsive to

FolamiR-34a, tumor bearing animals were intravenously administered 0.8 mg/kg (1
nmol) of FolamiR-34a every three days for a total of ten doses. Tumor growth was
monitored by MRI during the course of the study and the resulting volume
measurements generated from the MRI data indicate that FolamiR-34a reduces
tumor growth compared to animals administered the control folate-conjugate
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Fig. 2.18. KrasLSL G12D/+ ; T rp53f lx/f lx lung adenocarcinomas
express FR. A) Fluorescent imaging ligand OTL38 (On Target
Laboratories, LLC., West Lafayette, IN; FR-targeting ligand
conjugated to a near infrared (NIR) dye) is preferentially
retained in lung tumors and cleared from normal healthy tissue.
KrasLSL G12D/+ ; T rp53f lx/f lx mice were injected with 5 nmol of
OTL38 eight weeks after tumor induction and sacriﬁced 24 hours
post injection. A non-induced healthy mouse was used as a control.
RC, right caudal lobe; RM, right medial lobe; RA, right accessory
lobe, RCr, right cranial lobe; L, left lobe. B) Histological view of
right lung lobes from mice treated with OTL38. Left, NIR imaging
of whole organ view with matching H&E stained slide. Right, high
magniﬁcation images of tumorous and healthy tissue. H&E images
represent the type of tissue shown in bright ﬁeld and near infrared
images. Scale bar: 50 um; Inset: 20 um. Numbered boxes correlate
with numbers on high magniﬁcation images. C) Whole organ view
of lung lobes from mice treated with OTL38 (5 nmoles) in the
presence or absence of 100-fold molar excess of folate-glucosamine
(n = 3 per group). D) Representative histological views of tissues
from (C). Figure shows low magniﬁcation H&E stained tissues with
corresponding high magniﬁcation images of tumor tissue. On right,
whole organ NIR image view with matching high magniﬁcation NIR
images. H&E images represent the type of tissue shown in near
infrared images. Squares in low magniﬁcation H&E image correlate
with images shown in high magniﬁcation. Scale bar: 20 um. From
Orellana et al. (2017). Reprinted with permission from AAAS.
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(Figure 2.19A,B,C). Tumor size was statistically unchanged in animals administered
FolamiR-34a while tumor size in FolamiR-NC treated mice increased 1.5-fold
relative to the ﬁrst day of dosing.

A similar response was observed at the

histological level upon termination of the study (Figure 2.19D,E). Quantiﬁcation of
histological sections indicates a statistically signiﬁcant, 1.8-fold reduction in tumor
burden in lungs harvested from FolamiR-34a treated mice relative to FolamiR-NC
treated mice. Similar to the miR-34a copy number increase observed in MBA-231
xenografts, copy number of miR-34a in the excised lung tumor tissue was 3 fold
higher than in the tumors extracted from mice administered the control (Figure
2.16B). To validate that miR-34a was acting to repress endogenous target genes,
transcript levels of the miR-34a targets, BCL-2, MET, and MYC were quantiﬁed.
Both BCL-2 and MYC were statistically downregulated in tumors harvested from
mice administered FolamiR-34a, conﬁrming miR-34a activity on endogenous target
genes (Figure 2.19F).

2.5

Discussion
MiRNAs are exceptional candidates for combating many diseases such as cancer;

however, their therapeutic power is dwarfed by the lack of safe, robust, speciﬁc, and
efficient delivery methods. In theory, miRNAs are ideal therapeutic candidates.
Firstly, miRNAs are small, and because the kinetics of tumor uptake is inversely
proportional to the size of the particle, miRNAs should easily penetrate the dense
architecture of the tumor and the microenvironment [177]. Secondarily, due to basal
expression of some therapeutically-relevant miRNAs in noncancerous cells, slight
changes in cellular miRNA concentrations imposed following delivery are unlikely to
produce toxic side e↵ects. However, these same doses may prove lethal for cancerous
cells, especially in cells that are addicted to loss of the delivered miRNA[6]. Thirdly,
the pleotropic and promiscuous nature of miRNAs could make a single miRNA
analogous to a multi-drug chemotherapeutic cocktail through targeting various
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Fig. 2.19. Targeted replacement of miR-34a via FolamiR has beneﬁcial
e↵ects in a murine model of lung adenocarcinoma. A) MRI-measured
tumor burden following FolamiR-34a treatment (n = 3 or 5, error bars
represent mean ± s.e.m., statistical analysis performed with a twoway ANOVA and Bonferroni post hoc tests, **, P < 0.01). Arrows
represent treatment times (0.8 mg/kg:1 nmol intravenous injection;
total 10). B) Representative MRI images and 3D renders of mice
treated with FolamiRs during (day 8) and at the end of treatment
period (day 29). C) Tumor/whole lung ratios at the indicated times
showing the percentage of lung volume occupied by tumors. Error
bars represent mean ± s.d., statistical analysis performed with a oneway ANOVA, *, P < 0.05.D). Representative H&E stained tissue of
the left lobe of animals from each treatment group. Scale bars = 1mm.
E) Overall tumor burden is calculated from total tumor area averaged
from three histological sections obtained from each treated animal
relative to the total area of the lung. (Bars indicate the median,
FolamiR-NC: n=3, FolamiR-34a: n=5; unpaired t-test). F) miR34a target genes, Met, Myc, and Bcl-2 were evaluated by qRT-PCR,
normalized to Actin, and graphed relative to FolamiR-NC treated
tumors. (Bars indicate the median, unpaired t-test: *, P < 0.05)
From Orellana et al. (2017). Reprinted with permission from AAAS.
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complementary pathways at the same time[41]. It is therefore unlikely that acquired
resistance,

which

is

an

unforeseen

hallmark

of

most

targeted

cancer

therapeutics[103], would occur.
Although these strengths suggest that miRNA-therapeutics may be powerful
against diseases such as cancer, the power of miRNA therapeutic use is stiﬂed due
to lack of delivery methods that allow the miRNAs to reach and penetrate the
targeted tissues without unwanted toxicity. Due to the low stability of RNA in
serum,

miRNAs

have

been

packed

inside

various

protective

vehicles

[193, 63, 28, 30, 45, 121, 36, 4, 185]. Unfortunately, the added beneﬁt of protecting
the miRNA cargo comes with harmful side e↵ects.

One way to avoid

vehicle-associated toxicity is to remove the vehicle entirely. This high-risk approach
requires that the miRNA bases are heavily modiﬁed to protect the miRNA from
nucleases or that the miRNA is targeted and internalized rapidly.
The data presented herein supports conjugating a therapeutically relevant
miRNA directly to a targeting ligand whose receptor is overexpressed on cancerous
cells. We show that miR-34a, when conjugated to folate, enters the tumorigenic
cells speciﬁcally, efficiently targets both exogenous and endogenous targets, and
importantly

inhibits

tumor

growth

in

both

immunocompromised

and

immunocompetent models with no signs of toxicity at the tested therapeutic dose.
Surprisingly, the data suggest that folate, conjugated to the passenger strand, does
not impair loading into Argonaute as expected, but instead protects the miRNA
mimic from degradation. Although these ﬁndings are encouraging, some current
limitations of ligand-mediated delivery will need to be addressed, such as endosomal
sequestration of the therapeutic agent. Indeed, folate-conjugates are taken up via
the natural process of endocytosis. Thus endosomal entrapment of FolamiRs could
be a limiting step in achieving efficient targeting. We anticipate that inclusion of an
intermolecular endosomal escape mechanism incorporated into second-generation
FolamiRs could ensure robust cytosolic delivery of the therapeutic miRNAs.
Additionally, due to the heterogeneous nature of the tumor, selection of cells not
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expressing the folate receptor is an additional concern.

While other

folate-conjugates have shown success in their ability to deliver the conjugated agent
to tumor cells not expressing the receptor, whether or not a similar bystander e↵ect
occurs following FolamiR delivery will need to be evaluated.
As miRNA therapeutics continue to advance, it is imperative that relevant delivery
vehicles with limited toxicity are identiﬁed. The evidence presented here supports a
new method for vehicle-free miRNA delivery. This approach has completely removed
the toxic delivery vehicle without impairing miRNA delivery or activity. It is, thus,
highly plausible that miRNAs could be delivered at higher quantities and in the
absence of unwanted toxicity to treat various diseases such as cancer. While the data
presented are speciﬁc to miRNAs and siRNAs, as RNA-based therapeutics are further
explored, conjugating any relevant small RNA, such as piRNAs and tRNA fragments,
onto folate or other appropriate ligands to achieve fast, and tumor-speciﬁc uptake is
plausible.
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3. ENHANCING MICRORNA ACTIVITY THROUGH
INCREASED ENDOSOMAL RELEASE MEDIATED BY
NIGERICIN
All experiments and procedures were performed by Esteban A. Orellana unless
otherwise noted in the text.

3.1

Summary
The therapeutic promise of small RNA therapeutics (siRNAs, miRNAs) is not

only limited by the lack of delivery vehicles, but also by their inability to reach
intracellular compartments where they can be biologically active. In the previous
chapter it was shown that it is possible to deliver functionally active miRNAs via
receptor-mediated endocytosis [134]. This type of targeted therapy still faces one of
the major challenges in the delivery ﬁeld, endosomal sequestration. In this chapter,
a new method to promote endosomal escape using a small molecule is tested. The
strategy relies on the di↵erence in solute contents between nascent endosomes and
the cytoplasm: early endosomes are rich in sodium ions (Na+ ) while the intracellular
ﬂuid is rich is potassium ions (K+ ). If this di↵erence could be exploited by favoring
the inﬂux of K+ into the endosomes without the exchange for a osmotically active
ion (Na+ ), the net di↵erence in solute contents would be enough to cause a osmotic
di↵erential leading to endosome swelling and bursting. One molecule that is able to
exchange K+ for an osmotically inactive proton ion is the ionophore nigericin. Via
generating an intermolecular miRNA delivery vehicle, containing a ligand, in this
case folate, and nigericin we achieve escape of folate-RNA conjugates (e.g. FolamiRs)
from their entrapping endosomes into the cytoplasm where they can bind the RNA
Induced Silencing complex (RISC) and activate the RNAi response.
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3.2

Introduction
The therapeutic prospect of miRNA replacement therapies relies on the

reintroduction of small synthetic RNA molecules that mimic endogenous miRNAs in
cells that have lost them with the ﬁnal goal of restoring cellular pathways that could
stop pathogenesis. However, a major constraint in the transition of miRNA mimics,
and other small RNAs (small interfering RNA, siRNA; antisense oligonucleotides),
into the clinic has been the lack of efficient delivery systems. Encapsulation of small
RNAs, for instance, has had mixed results in the clinic with clinical trials showing
toxicity and limited efficacy [201].
protective delivery vehicles (e.g.
delivery-associated

toxicity,

poor

Some problems that come with the use of
liposomes,
transfection

micelles,
efficiency,

polymers) include
and

nonspeciﬁc

biodistribution [178].
Our previous work shows that these vehicle-related defects may be avoided by
eliminating the vehicle, attaching a miRNA to a folate ligand (FolamiR) [134]. This
approach can deliver functionally active miRNAs to cancer cells that overexpress
the folate receptor (FR) via receptor-mediated endocytosis with no signs of toxicity
(maximum tolerated dose >26.64 mg/kg) [134]. Thus, in the absence of toxicity,
the main factors limiting dosage would be two-fold: i) the internalization kinetics of
the folate-ligand bound to its receptor (endocytosis) and ii) the rate by which the
FolamiR can escape the endosome [133, 156].
We reasoned that since the internalization kinetics of FolamiRs are less
amendable and already quick [177, 189, 190], the development and inclusion of an
endosomal escape mechanism onto new generation FolamiRs could help overcome
the rate-limiting step of endosomal escape providing higher efficacy, and further
reducing toxicity. Endosomal escape of small RNAs (and other biologics) has been
recognized as a major hindrance in the path to translating RNA therapeutics into
the clinic. For that reason e↵orts have been focused on developing strategies to
enhance endosomal release and secure cytosolic delivery [175].

Proteins and
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peptide-based agents (i.e. cell penetrating peptides, CPPs) are often used to achieve
cytosolic release of oligonucleotides [175]. For instance, the EB1 peptide, derived
from penetratin, is a CPP with endosomolytic properties that facilitates transport
of active siRNAs into cells [107].

Similarly, the inclusion of inﬂuenza-derived

fusogenic peptide diINF-7 has been shown to enhance endosomal escape of siRNAs
when complexed with lipid carriers [130]. However, the use of peptides is often toxic
and may contribute to increased immunogenicity [46], which is already a major
concern in RNA therapeutics. Another approach to improve endosomal release of
nucleic acids is the use of “proton sponges” that can promote endosomal swelling by
inducing counterion uptake that leads to increased osmotic pressure [7].

The

practicality of using this strategy in the clinic is dampened due to the large
concentration of compound needed to achieve efficient endosomal bursting [7].
Photochemical internalization (PCI) is another alternative to increase endosomal
escape of siRNAs, but this approach is greatly limited to speciﬁc sites where light
can be used to trigger endosome lysis, which reduces its practical use in the clinic
[129].
We recently described a novel method to facilitate the escape of biologics from
entrapping endosomes and in that study provided preliminary evidence for the
potential use of this method to improve the escape of small RNAs from endosomes
[144].

The strategy relies on the di↵erence in solute contents between nascent

endosomes and the cytoplasm: endosomes are rich in sodium ions (Na+ ) while the
intracellular ﬂuid is rich is potassium ions (K+ ). The method exploits this di↵erence
by using a small molecule, nigericin [163, 56], that exchanges K+ for osmotically
inactive proton (H+ ) to achieve balance in charge without release of a compensatory
solute (Na+ ) thus causing a osmotic di↵erential that leads to endosome swelling and
bursting [144].
Herein, we show that this approach could be useful to overcome endosomal
entrapment of small RNAs delivered by folate. The data presented here suggest
that ligand-targeted delivery of nigericin into endosomes can facilitate the escape of
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RNA cargo (e.g. miRNAs, siRNAs) from their entrapping endosomes, helping the
small RNAs to become available in the cytoplasm, engage the RNA Induced
Silencing complex (RISC) and improve their RNAi activity (see proposed model in
Figure 3.1). Developing a highly speciﬁc delivery platform (i.e. FolamiRs) with
increased endosomolytical properties could be useful towards achieving signiﬁcant
therapeutic e↵ects at low concentrations and without unwanted toxicity for future
in vivo applications.

3.3

Materials and methods

3.3.1

Cell culture

MDA-MB-231 cells (MB-231, HTB-26) and KB carcinoma cells (CCL-17), both
mycoplasma-free as determined by testing for mycoplasma contamination via
MycoAlert Mycoplasma Detection Kit (Lonza), were grown in RPMI 1640 medium,
no folic acid (Life Technologies) supplemented with 10% fetal bovine serum (Sigma),
penicillin (100 U/ml ), and streptomycin (100 ug/ml) (HyClone, GE Healthcare Life
Sciences), and maintained at 37 C in 5% CO2 . Authentication of MB-231 and KB
cells was performed using short tandem repeat proﬁling [American Type Culture
Collection (ATCC)].

3.3.2

Preparation of pyridyldisulﬁde amide derivative of nigericin

Folate-EDA, folate-cys and folate-DBCO synthesis was performed by Loganthan
Rangasamy as previously described [134]. Folate-nigericin synthesis was performed
by Loganthan Rangasamy as described in [144], nigericin free acid (0.035 mmol),
Py-SS-(CH2 )2 NH2 (0.052 mmol), HATU (0.052 mmol), and DIPEA (0.069 mmol)
were dissolved in anhydrous CH2 Cl2 (2.0 mL) and stirred under argon at room
temperature overnight (Figure 3.2A). Progress of the reaction was monitored by
liquid chromatographymass spectrometry (LC-MS, Figure 3.2B). After complete
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Fig. 3.1. Proposed mechanism of action of endosomal escape of
RNA cargo mediated by ligand-targeted delivery of nigericin.
Internalization of Fol-Nig-RNA conjugates is mediated by
endocytosis.
The nascent vesicle is rich in extracellular ﬂuid
with a high concentration of Na+ (blue shading), while the
intracellular space contains high levels of K+ (yellow shading). Upon
ligand-targeted delivery, nigericin, a K+ /H+ antiporter, translocates
to the endosomal membrane (di-sulﬁde bond, red linker) causing
an inﬂux of K+ (green shading) in exchange for H+ . The exchange
of K+ for the osmotically inactive H+ leads to build up of osmotic
pressure which causes endosomal swelling and release of RNA cargo
into the cytosol.
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conversion of nigericin free acid, the crude reaction mixture was subjected to
puriﬁcation by R-HPLC, (mobile phase A = 10 mM ammonium acetate, pH = 7;
organic phase B = acetonitrile; method: 0% B to 100% B in 35 min at 13 ml/min)
and furnished nigericin-SS-amide derivative 55% yield.

LC-MS (A = 10 mM

ammonium bicarbonate, pH = 7; organic phase B = acetonitrile; method: 0% B to
100% B in 15 min) RT = 9.15 min (M + N H4+ = 910.5)

3.3.3

Preparation of folate-nigericin conjugate

Folate-nigericin synthesis was performed by Loganthan Rangasamy as previously
described [144]: DIPEA was added dropwise to a stirred solution of folate-Cys (0.004
g, 0.007 mmol, 1.5 eq.) and pyridyldisulﬁde amide derivative of nigericin (0.004 g,
0.005 mmol, 1.0 eq.) in DMSO (Figure 3.3A). The reaction mixture continued to
be stirred at room temperature. Progress of the reaction was monitored by LCMS (Figure 3.3B). After complete conversion of folate-nigericin, the crude reaction
mixture was puriﬁed by RP-HPLC, (mobile phase A = 10 mM ammonium acetate,
pH = 7; organic phase B = acetonitrile; method: 0% B to 40% B in 35 min at 13
ml/min) and furnished folate-nigericin 65% yield. LC-MS (A = 10 mM ammonium
bicarbonate, pH = 7; organic phase B = acetonitrile; method: 0% B to 100% B in 7
min) RT = 4.0 min (M + H + = 1440.0).

3.3.4

Preparation of folate - nigericin - DBCO

Folate-nigericin-DBCO synthesis was performed by Loganthan Rangasamy as
previously described [144]: DIPEA (0.0013 g, 0.010 mmol, 1.5 eq.)

was added

dropwise to a stirred solution of folate-nigericin (0.010 g, 0.0069 mmol, 1 eq.) and
NHS-DBCO (0.003 g, 0.0076 mmol, 1.5 eq.) in DMSO (Figure 3.4A). The reaction
mixture continued to be stirred at room temperature. Progress of the reaction was
monitored

by

LC-MS

(Figure

3.4B).

After

complete

conversion

of

folate-nigericin-DBCO, the crude reaction mixture was puriﬁed by RP-HPLC,
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Fig. 3.2. Production of the pyridyldisulﬁde amide derivative of
nigericin. A) Synthesis scheme. B) LC-MS proﬁle of pyridyldisulﬁde
amide derivative of nigericin.
Figure prepared by Loganthan
Rangasamy. Reprinted with permission from Rangasamy et al. 2018.
New Mechanism for Release of Endosomal Contents: Osmotic Lysis
via Nigericin-Mediated K+/H+ Exchange.Bioconjugate Chemistry.
Copyright (2018) American Chemical Society.
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Fig. 3.3. Preparation of folate-nigericin conjugate. A) Synthesis
scheme. B) LC-MS proﬁle of folate-nigericin conjugate. Figure
prepared by Loganthan Rangasamy. Reprinted with permission
from Rangasamy et al. 2018. New Mechanism for Release of
Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+
Exchange.Bioconjugate Chemistry.
Copyright (2018) American
Chemical Society.
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Fig. 3.4. Preparation of folate-nigericin-DBCO conjugate. A)
Synthesis scheme.
B) LC-MS proﬁle of folate-nigericin-DBCO
conjugate. Figure prepared by Loganthan Rangasamy. Reprinted
with permission from Rangasamy et al. 2018. New Mechanism
for Release of Endosomal Contents: Osmotic Lysis via NigericinMediated K+/H+ Exchange.Bioconjugate Chemistry. Copyright
(2018) American Chemical Society.

(mobile phase A = 10 mM ammonium acetate, pH = 7; organic phase B =
acetonitrile; method: 0% B to 50% B in 35 min at 13 ml/min) and furnished
folate-nigericin amide 65% yield. LC-MS (A = 10 mM ammonium bicarbonate, pH
= 7; organic phase B = acetonitrile; method: 0% B to 100% B in 12 min) RT = 3.9
min (M + H + = 1728.4).
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3.3.5

Preparation of folate - nigericin - DBCO - miR-34a (Fol-Nig-34a)
conjugate

miRNA duplexes were constructed as previously described [134].

Brieﬂy, a

bi-orthogonal click reaction was performed between folate-nigericin-DBCO and
azide modiﬁed antisense miR-34a (or scramble). Click reaction was performed at a
1:10 molar ratio (azide oligo: folate-nigericin-DBCO) at room temperature in water
for eight hours and then cooled to 4 C for four hours.

Unconjugated

folate-nigericin-DBCO was removed from the reaction using Oligo Clean and
Concentrator (Zymo Research) per manufacturer instructions.

Conjugation was

veriﬁed using 15% TAE native PAGE and MALDI spectral analysis.

After

conjugation, the miR-34a sense strand was annealed to the folate-nigericin-miR-34a
antisense conjugate. Folate-nigericin-DBCO-miR-34a antisense and miR-34a sense
were mixed in an equal molar ratio (1:1, ﬁnal concentration 20uM each) in annealing
bu↵er: 10mM Tris bu↵er, pH 7 (Sigma), supplemented with 50mM NaCl (Sigma),
and 1mM EDTA (Sigma), and incubated at 95 C for ﬁve min, cooled slowly to room
temperature and then stored at -80 C. This compound is referred to as Fol-Nig-34a.
For cellular uptake experiments, an Atto-647N ﬂuorophore was attached to the 50
end of the miR-34 antisense oligo and was used in the annealing step generating the
following compounds: Fol-34a-Atto647N, and Fol-Nig-34a-Atto647N.

3.3.6

Stability assay in serum

Stability assays were performed as previously described[134]. Brieﬂy, Fol-Nig-34a
conjugates were incubated in 50% fetal bovine serum (Sigma) in water at 37 C for
the indicated times. RNA samples were collected and analyzed using 15% TAE
polyacrylamide

gel

electrophoresis

(PAGE).

The

reducing

agent

tris(2-carboxyethyl)phosphine (TCEP) was used as a positive control for nigercin
reduction (5mM, 20 min at room temperature).
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3.3.7

Preparation of folate-cyanide 5 (Fol-Cy5) dye conjugate

Folate-cyanide 5 synthesis was performed by Loganthan Rangasamy as previously
described [144]. DIPEA (0.0004 g, 0.0032 mmol, 2 eq.) was added dropwise to a
stirred solution of folate-EDA (0.0008 g, 0.0016 mmol, 1 eq.) and NHS-Cyanide 5
(Cy5, 0.001 g, 0.001 mmol, 1.1 eq.) in DMSO (Figure 3.5A). The reaction mixture
continued to be stirred at room temperature. Progress of the reaction was monitored
by LC-MS (Figure 3.5B). After complete conversion of folate-Cy5, the crude reaction
mixture was puriﬁed by RP-HPLC. (mobile phase A = 10 mM ammonium acetate,
pH = 7; organic phase B = acetonitrile; method: 0% B to 50% B in 35 min at 13
ml/min) and furnished folate-Cy5 dye conjugate in 85% yield. LC-MS (A = 10 mM
ammonium bicarbonate, pH = 7; organic phase B = acetonitrile; method: 0% B to
50% B in 12 min) RT = 2.40 min (M + H + = 949.2).

3.3.8

Preparation

of

folate-nigericin-cyanide

5

(Fol-Nig-Cy5)

dye

conjugate
Folate-nigericin-cyanide 5 synthesis was performed by Loganthan Rangasamy.
DIPEA (0.0004 g, 0.0032 mmol, 2. eq.) was added dropwise to a stirred solution of
Folate-nigericin (0.0023 g, 0.0016 mmol, 1 eq.)

and NHS-Cy5 (0.001 g, 0.0016

mmol, 1 eq.) in DMSO (Figure 3.6). The reaction mixture continued for stirring at
room temp.

Progress of the reaction was monitored by LCMS. After complete

conversion of Folate-nigericin-Cy5, the crude reaction mixture was puriﬁed by
RP-HPLC, (mobile phase A = 10 mM ammonium acetate, pH = 7; organic phase B
= acetonitrile; method: 0% B to 50% B in 35 minutes at 13 ml/min) and furnished
folate-nigericin-Cy5 65% yield. LC-MS (A = 10 mM ammonium bicarbonate, pH =
7; organic phase B = acetonitrile; method: 0% B to 100% B in 12 minutes) RT =
7.05 min (M + H + = 1906.0).
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Fig. 3.5. Preparation of folate-Cyanide 5 (Fol-Cy5) conjugate. A)
Synthesis scheme. B) LC-MS proﬁle of Fol-Cy5 conjugate. Figure
prepared by Loganthan Rangasamy. Reprinted with permission
from Rangasamy et al. 2018. New Mechanism for Release of
Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+
Exchange.Bioconjugate Chemistry.
Copyright (2018) American
Chemical Society.
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Fig. 3.6. Preparation of folate-nigericin-cyanide 5 (Fol-Nig-Cy5)
conjugate. A) Synthesis scheme. B) LC-MS proﬁle of Fol-Nig-Cy5
conjugate. Figure prepared by Loganthan Rangasamy.
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3.3.9

Flow Cytometry

Flow cytometry was performed as previously described[134]. FR positive human
MB-231 cells or KB carcinoma cells were detached by trypsinization, washed twice
in ice-cold phosphate bu↵ered saline (PBS; pH 7.4) and resuspended to a density
of 1x107 cells/ml in serum free medium. Cell viability was determined by trypan
blue exclusion and cells were only used if the viability of cells was >80%. Next, ﬂow
cytometric analyses were performed following standard protocols. One-hundred uL
of the cell suspension was incubated with Fol-34a-Atto647N, Fol-Nig-34a-Atto647N,
or folate-cyanide 5 (Fol-Cy5) [144] (50nM) in the absence or presence of 10 to 100
fold molar excess of folate glucosamine conjugate. Cells were incubated at 4 C for 20
min and washed twice with ice cold PBS and analyzed by ﬂow cytometric analysis
using LSR Fortessa ﬂow cytometer (BD Biosciences, San Jose, CA, USA). Data was
analyzed using FlowJo software v10 (Tree Star, Inc, Ashland, Ore).

3.3.10

Live Cell Imaging

Brieﬂy, eight-well chambered slides with a glass cover slip bottom (Lab-TekTM
Chambered Coverglass, Thermo Fisher Scientiﬁc, Denmark) were pre-treated with
Poly-D-Lysine (0.1 mg/ml ; Sigma-Aldrich) for ﬁve min, washed with PBS and airdried for ﬁve min. KB or MB-231 cells were plated onto prepared slides one day before
the experiment at 2x104 cells/well and maintained in RPMI 1640 medium, no folic
acid (Life Technologies) supplemented with 10% fetal bovine serum (Sigma), 100U/ml
penicillin and 100ug/ml streptomycin (Hyclone, GE Healthcare Life Sciences) at 37 C
in 5% CO2 . The slides were placed in a Nikon A1Rsi confocal microscope with a
resonant scanner and piezo z-drive (Nikon Instruments Inc.), 20X objective Plan Apo
0.75 NA, equipped with a Tokai hit live imaging chamber (INU-TIZ-F1; Tokai Hit
Corp., Japan) with temperature set to 37 C and continuous bubbling of 5% CO2
into water. Image acquisition using NIS-elements software 4.5 (Nikon Instruments
Inc., Japan) on a single focal plane was conducted for 3 h after addition of Fol-Cy5,
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Fol-Nig-Cy5, Fol-34a-Atto647N or Fol-Nig-34a-Atto647N conjugates (50 nM). Images
were further analyzed using ImageJ 2.0.0 (NIH).

3.3.11

Segmentation and quantiﬁcation of subcellular vesicles

Segmentation and quantiﬁcation of subcellular vesicles was performed using the
segmentation and quantiﬁcation of subcellular shapes (Squassh) protocol [138, 148] in
the Mosaic plugin in ImageJ V2.0 (NIH) using the following segmentation parameters:
regularization: 0.1, minimum object intensity: 0.160.

3.3.12

Live cell proliferation assay

KB cells were incubated with 1% V/V NucLight Red Lentivirus (Essen
Bioscience, Cat. No 4476), seeded on 96-well plates (Corning 3603; 2,000 cells/well)
and incubated at 37 C with 5% CO2 overnight.

The next day, new medium

containing di↵erent concentrations of the following reagents was added to the wells:
vehicle (DMSO), tubulysin, nigericin, and folate nigericin. The plate was placed in
an Icucyte S3 instrument (Essen Bioscience), each well was imaged using standard
mode scan with a 10X objective, phase and red ﬁlter acquisition, and imaged every
four hours for 24 h. Each treatment consisted of three wells with ﬁve ﬁelds of view
per well. Cell proliferation was quantiﬁed by counting the number of ﬂuorescent
nuclei over 24 h using the Incucyte S3 Software (Essen Bioscience).

Data was

exported and analyzed using Graphpad Prism v.7. Cell growth is represented as
conﬂuence (%) relative to time 0.

To determine the dose that causes growth

inhibition of at least 50% (GI50 ), the 24-hour data points were selected and
normalized to vehicle treated cells.
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3.3.13

RNA immunoprecipitation assay

RNA precipitation assays were performed as previously described [123, 122].
Brieﬂy, MB-231 cells transfected with a miR-34a mimic were used as control.
MB-231 cells (7x105 cells/well) were seeded into 6-well plates and maintained
overnight in RPMI 1640 medium, no folic acid (Life Technologies) supplemented
with 10% fetal bovine serum (Sigma),

100U/ml penicillin and 100ug/ml

streptomycin (Hyclone, GE Healthcare Life Sciences) at 37 C in 5% CO2 . The next
day, medium was replaced with 800 uL of fresh complete medium. Transfection of
miR-34a

mimic

(Ambion,ﬁnal

concentration

6nM)

was

performed

with

Lipofectamine RNAimax (Life Technologies) by mixing 100 uL serum free medium
(SFM) containing mir-34a mimic (Ambion) and 100 uL SFM with 7.5 uL of
Lipofectamine RNAimax (Life Technologies), incubated at room temperature for 5
min and then added to the wells. Cells were incubated for 4 h at 37 C in 5% CO2
and media was replaced with 2 mL of fresh complete medium. For FolamiR-34a or
Fol-Nig-34a treatments, MB-231 cells (8x105 cells/well) in complete medium were
seeded into 6-well plates containing FolamiR-34a or Fol-Nigericin-34a diluted in 1
mL serum free RPMI medium to a ﬁnal concentration of 100 nM. After 24 h cells
were put on ice, washed twice with ice cold PBS and immersed in 1 mL PBS. Cells
were cross-linked at 400 mJ per cm2 and then again at 200 mJ per cm2 in an UV
cross-linker (XL-1000, SpectroLinker). Cells were scraped directly into lysis bu↵er
(1 PBS, 1% vol/vol NP40 substitute, 0.5% wt/vol sodium deoxycholate and 0.1%
wt/vol SDS). Next, the lysates were centrifuged in a prechilled tabletop
ultracentrifuge at 21,000 RPM for 20 min at 4 C. Cleared lysates were incubated
with Dynabead Protein A beads (Life Technologies) prepared with 2A8 anti-AGO
[123, 126] (Millipore, MABE56) or normal mouse IgG (Millipore, 12-371) for 90 min
at 4 C, washed and resuspended as previously described [123]. RNA was isolated
using Qiazol reagent (Qiagen) followed by ethanol precipitation.

Reverse

transcription was performed using the miRscript II RT kit (Qiagen) using the
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HiSpec bu↵er. Real-time PCR was conducted using miScript SYBR Green PCR Kit
(Qiagen) with the following primers: RNU6B (non-target RNA, Qiagen MiScript
primer assay), let-7b-1 (positive control, Qiagen MiScript primer assay) and mir-34a
(Qiagen MiScript primer assay).
2

��Ct

3.3.14

Real time PCR data was analyzed using the

method [100, 195] and expressed as fold enrichment.

Protein isolation and western blotting

MB-231 cells were collected in RNA Later (Life Technologies) and stored at
-80 C. Tumor tissues (50mg) were placed in 2 mL collection tubes containing
radioimmunoprecipitation assay bu↵er (1 X phosphate-bu↵ered saline, 1% NP-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 X protease inhibitor).
Cells were incubated for 10 min on ice and centrifuged for 10 min at 4 C (13,000
RPM), supernatant was collected, 50ug of protein was resolved on 12% TGX gels
(Bio-Rad) and transferred to polyvinylidene diﬂuoride (PVDF) membranes. Revert
Total Protein Staining kit (Licor) was used as protein loading control following the
manufacturer’s instructions. 2A8 anti-AGO (1:1000, Millipore, MABE56) primary
antibody was used for Argonaute 2 detection. Protein detection was performed
following incubation with secondary antibodies (Licor), membranes were washed
and signal was acquired using Licor Odyssey CLX (Licor).

3.4

Results

3.4.1

Folate-nigericin-miRNA conjugation and stability in serum

Since nigericin needs to dissociate from the folate carrier and localize to the
endosomal membrane to be able to induce endosome swelling (exchange intracellular
K+ for H+ ), an intermolecular disulﬁde linkage was incorporated between nigericin
and the folate-RNA conjugate (Figure 3.7A). Folate-nigericin-miRNA conjugation
was achieved as previously described [134] by using click chemistry [113] and
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conjugation was veriﬁed by polyacrylamide gel electrophoresis (PAGE) analysis
(Figure 3.7B) and matrix-assisted laser desorption/ionization (MALDI) spectral
analysis. Disulﬁde linkage reduction was veriﬁed by PAGE analysis by a band size
shift upon tris(2-carboxyethyl)phosphine (TCEP) treatment (Figure 3.7B). To test
the stability of the disulﬁde linkage Fol-Nig-34a compounds were exposed to 50%
serum. No signs of Fol-Nig-34a reduction were observed for more than four hours
(Figure 3.7C) leaving open the possibility that premature reduction upon systemic
delivery could occur after 4 h. Our previous results using FolamiRs in vivo show
that less than four hours is enough time for the folate conjugates to localize and be
internalized into the intended tissues [134].

3.4.2

Folate-nigericin-miRNA conjugate uptake is mediated by the folate
receptor

Due to the high affinity of the ionophore nigericin to cellular membranes it was
important to verify that uptake of Fol-Nig-miRNA conjugates was mediated by the
FR. For that purpose, expression of the FR by ﬂow cytometric analyses was veriﬁed in
MB-231 cells and KB cells as previously reported [134, 136] by using a folate-cyanine
5 conjugate (Fol-Cy5; Figure 3.8A). Next, to visualize cellular uptake of miR-34a in
the absence or presence of nigericin, an Atto-647N ﬂuorophore was attached to the 50
end of miR-34a-5p strand generating Fol-34a-Atto647N and Fol-Nig-34a-Atto647N .
Speciﬁcity of cellular uptake of Fol-34a-Atto647N or Fol-Nig-34a-Atto647N conjugates
was conducted in the presence or absence of folate glucosamine as a competitor (Figure
3.8B,C). Both conjugates were taken up by MB-231 and KB cells only in the absence of
folate glucosamine suggesting that the uptake is FR mediated. Furthermore, minimal
uptake in the absence of folate conjugation (gymnotic uptake) was observed at the
dose used in the experiments (Figure 3.9). Taken together these results suggest that
Fol-Nig-miRNA uptake is mediated by FR.
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Fig. 3.7. Evaluation of folate-nigericin-miRNA conjugation and
stability in serum measured by 15% native TAE PAGE. A)
Scheme of folate-nigericin-miR34a conjugation. B) Gel red stained
polyacrylamide gel.
Each lane was loaded with 200 pmol of
unconjugated oligo (Duplex) or folate-miRNA. + indicates the
presence of a particular ligand conjugated to miR-34a duplex. PAGE
results suggest successful conjugation of folate-miRNA compounds as
visualized by the shift in mobility. The band shift in lane 4 indicates
reduction of the disulﬁde bond between nigericin and folate-miRNA.
TCEP, reducing agent tris(2-carboxyethyl)phosphine. B) Gel red
stained polyacrylamide gel following resolution of folate-nigericinmiRNA after 50% serum exposure for di↵erent periods of time. TCEP
(5mM) is included as a positive control.

82

Fig. 3.8. Folate-nigericin-miRNA conjugate uptake is mediated by
the folate receptor. A) Conﬁrmation of folate receptor expression in
MB-231 breast cancer cells and in KB carcinoma cells. Histograms
represent overlaid ﬂow cytometry data as a percentage of unstained
and Folate-Cyanate 5 (Fol-Cy5) cells. Displacement of Fol-34aAtto647N (B) or Fol-Nig-34a-Atto647N (C) binding from MB-231 and
KB cells (50 nM, 4 C) in the presence of 100-fold excess of folateglucosamine conjugate. Histograms represent overlaid ﬂow cytometry
data as a percentage of unstained, and Fol-34a-Atto647N or Fol-Nig34a-Atto647N stained cells.
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Fig. 3.9. Folate-nigericin-miRNA conjugate uptake is not mediated
by gymnosis. Histograms represent overlaid ﬂow cytometry data as a
percentage of unstained, Fol-34a-Atto647N, Fol-Nig-34a-Atto647N or
miR-34a-Atto647N stained MB-231 and KB cells (50 nM, 4 C).

3.4.3

Ligand-targeted delivery of nigericin causes endosomal swelling

To track the release of cargo from endosomes, cyanide 5 (Cy5) was delivered
either with a folate-only or a folate-nigericin carrier, and the ﬂuorescent cellular
distribution was used as a surrogate for cargo localization. For that purpose, FR+
MB-231 cells were incubated with 50 nM of Fol-Cy5 or Fol-Nig-Cy5 and imaged
every two min for 1 h. Representative images of the cells at 15 min are presented in
Figure 3.10. The intracellular distribution of Cy5 was noticeably di↵erent in the
absence of nigericin. Cells treated with Fol-Cy5 show ﬂuorescent signal in their cell
membrane and individual punctate spots through the cytoplasm (Figure 3.10). In
contrast, cells treated with Fol-Nig-Cy5 show perinuclear distribution as string-like
dispersions with no clearly distinguishable punctate spots (Figure 3.10).
Next, to monitor the release of miR-34a in the absence or presence of nigericin,
FR+

KB

cells

were

incubated

with

50

nM

of

Fol-34a-Atto647N

or

Fol-Nig-34a-Atto647N and imaged every two min for 3 h. Representative images of
the cells at 2, 20, 40, 60 and 90 min are presented in Figure 3.11A. A signiﬁcant
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Fig. 3.10. Ligand-targeted delivery of nigericin promotes cargo
escape form endosomes. Representative confocal images of MB-231
cells treated with Fol-Cy5 or Fol-Nig-Cy5 (50 nM) at 15 min post
treatment.
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di↵erence in the intracellular distribution of Fol-Nig-34a-Atto647N was visible as
early as 30 min after treatment when noticeably larger vesicles were observed in the
cells treated with Fol-Nig-34a-Atto647N conjugate compared to the vesicles of cells
treated Fol-34a-Atto647N (see Figure 3.11B for quantiﬁcation).

The ﬂuorescent

signal in Fol-34a-Atto647N treated KB cells appears to localize mainly in
intracellular vesicles, observed as punctate, for the duration of the acquisition
period (shown up to 2h post treatment). In contrast, the ﬂuorescent signal in cells
treated with Fol-Nig-34a-Atto647N appears as cloudy dispersions inside the cytosol,
which could suggest release of miR-34a-Atto647N from endosomes.

This could

explain the reduced number of ﬂuorescent punctate detected in cells treated with
Fol-Nig-34a-Atto647N (Figure 3.11C). Taken altogether, these data suggest that
ligand-targeted delivery of nigericin promote escape of cargo from entrapping
endosomes.

3.4.4

Nigericin mediates endosomal escape of miRNA cargo

To conﬁrm that nigericin can mediate endosomal escape, we used a functional
assay to monitor RNAi activity using miR-34a. Luciferase reporter assays were
performed in MB-231 cells that express a reporter for miR-34a [134].

These

cell-based experiments indicated a rapid reduction in luciferase activity in
Fol-Nig-34a treated cells as soon as 18h post treatment (reaching ⇠40% knockdown)
and after 48h reaching 85% (Figure 3.12A). Interestingly, this reduction in luciferase
activity was not observed in Fol-Nig-NC treated cells suggesting that the e↵ect is
speciﬁc to the presence of miR-34a and not due to a side e↵ect caused by nigericin
mediated toxicity. To eliminate that possibility we conducted cellular toxicity assays
and the results show that the ﬁrst signs of toxicity related to nigericin compounds
(folate-nigericin) can be visualized at concentrations >1000nM (Figure 3.12B). To
further test the hypothesis that nigericin facilitates the release of RNA cargo into
the cytoplasm,

we performed RNA immunoprecipitation (RIP) assays by
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Fig. 3.11. Nigericin causes endosomal swelling. A) Representative
confocal images of KB cells treated with Fol-34a-Atto647N or FolNig-34a-Atto647N at di↵erent time points. Comparison of ﬂuorescent
object size (B) and object number (C) between Fol-34a-Atto647N
or Fol-Nig-34a-Atto647N treated KB cells at di↵erent time points
is also shown. (n = 4, error bars: mean ± s.d.). Segmentation
and quantiﬁcation of subcellular vesicles was performed using the
segmentation and quantiﬁcation of subcellular shapes (Squassh)
protocol [138, 148]. Statistical analysis performed with Student’s Ttest,*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not signiﬁcant.
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immunoprecitating Argonaute (Ago) proteins [123, 122] in cells treated with
FolamiR-34a or Fol-Nig-34a (Figure 3.12C). We reasoned that since RNA-induced
silencing complex (RISC) programming is triggered by the appearance of double
stranded RNA in the cytoplasm (i.e. miRNA) and Ago proteins localize di↵usely in
the cytoplasm and nucleus [99, 96] loading of miR-34a-5p into Ago would be
indicative of cytosolic release.

The results show that miRNA-34a-5p is more

abundant in Ago RIP following folate-nigericin delivery (⇠6 fold) compared to
delivery using folate only conjugation (Figure 3.12D). Ago did not pull down
RNU6B, as expected, but was associated with the positive control let-7b validating
the assay. Taken together, these results support the hypothesis that partial decrease
in luciferase activity is RNAi mediated and that the inclusion of nigericin in the
folate carrier can help miR-34a escape from endosomes and become available in the
cytoplasm to associate with Ago.

3.4.5

Inclusion of nigericin in the folate carrier enhances miRNA activity
in vitro

To test if the incorporation of nigericin into the folate carrier can enhance
miRNA activity in vitro we treated MB-231 miR-34a sensor cells with FolamiR-34a
or with Fol-Nig-34a. The results show a di↵erence in luciferase repression between
FolamiR-34a (⇠30% reduction in Renilla activity) and Fol-Nig-34a (⇠85% reduction
in Renilla activity, Figure 3.13) that could indicate that FolamiR-34a gets
entrapped inside endosomes by folate-targeted endocytosis. This could also explain
why miR-34a delivered by folate alone is not abundant in Ago RIP. To test the
hypothesis that the incorporation of nigericin in the folate carrier can lead to
enhanced miR-34a activity in culture we conducted dose-response studies comparing
FolamiR34a and Fol-Nig-34a. Taken together, these results support the hypothesis
that rapid release of miRNA cargo from endosomal vesicles mediated by nigericin
can improve miR-34a activity in culture.
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Fig. 3.12. Nigericin mediates endosomal escape of miRNA cargo. A)
E↵ect of Fol-Nig-34a on miR-34a sensor silencing in vitro. For FolNig-34a data points were normalized to Fol-Nig-NC (negative control:
scrambled miRNA). MiR-34a duplex treated cells were normalized to
untreated cells. Each experiment corresponds to n=3, 4 technical
replicates per treatment, 50 nM, statistical analysis performed with
one-way ANOVA and Bonferroni correction, (*, P < 0.05; ***, P <
0.001; ****, P < 0.0001). B) E↵ect of folate-nigericin on cell growth of
MB-231 cells. Data points were normalized to vehicle (DMSO). Error
bars: mean ± s.d. N= 6. C) RT-qPCR results following Ago RIP from
cells treated with FolamiR-34a or Fol-Nig-34a (100 nM). Transfected
miR-34a mimic was used as delivery control (6 nM). RNU6B: not
targeted control, let-7b: positive control. Experiments were repeated
twice. Error bars: mean ± s.d.
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Fig. 3.13. Incorporation of nigericin into the folate carrier can enhance
miRNA activity in vitro. Targeted silencing of miR-34a Renilla sensor
using Fol-Nig-34a in vitro. Error bars: mean ± s.d. Each experiment
corresponds to n=3, 4 technical replicates per treatment, statistical
analysis performed with two-way ANOVA and Bonferroni correction,
( **, P < 0.01; ***, P < 0.001); ****, P < 0.0001).

3.5

Discussion
Development of an e↵ective delivery strategy for targeted, tissue-speciﬁc delivery

of small RNAs can be achieved with the use of small ligands. The addition of a
ligand to a small RNA promotes its cellular uptake and trafficking, and although is a
key advantage to achieve the required speciﬁc biodistribution, it often su↵ers from a
major limitation, endosomal entrapment. Upon binding to the membrane receptor,
these ligands and the associated RNA cargo are internalized by receptor-mediated
endocytosis and loaded into early endosomes. The contents of the endocytic vesicles
are then sorted and trafficked intracellularly en route to the lysosome, which is where
the nucleic acid cargo will be degraded. To avoid lysosomal degradation, the ligandRNA conjugates need to escape from the endosome into the cytoplasm where they
can engage RISC and modulate gene expression. Thus, the clinical application of
small RNA therapeutics requires the development of delivery strategies that not only
can direct tissue-speciﬁc internalization, but also e↵ectively traffic the small RNA to
the cytoplasm reaching biologically relevant doses.
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Our previous research showed that it is possible to deliver a miRNA mimic to
cancerous cells by simply conjugating the passenger strand to a folate ligand with
no signs of toxicity at the therapeutic dose tested [134]. Because folate conjugates
are internalized via endocytosis, endosomal sequestration could be a limiting step in
achieving signiﬁcant clinical e↵ects.

We reasoned that the inclusion of an

intermolecular endosomal escape mechanism could ensure robust cytosolic delivery
of the RNA cargo and lead to enhanced miRNA activity. This approach relies on
the use of a small molecule, nigericin, that upon cellular internalization gets cleaved
from the folate carrier and localizes to endosomal membrane where it exchanges K+
and water for osmotically inactive proton (H+ ) causing endosomal swelling [144]. To
be e↵ective, nigericin release has to occur in a controlled manner and only within
the endosomes.

Our preliminary evidence suggest that folate-nigericin-miRNA

molecules are stable in 50% serum for at least four hours, which according to our
previous observations would be enough time for the conjugate to be internalized into
the target cells [134]. Premature cleavage and release of nigericin in circulation is a
concern and further in vivo experiments will be needed to evaluate this possibility.
The evidence presented here supports that the new method for endosomal
release of small RNAs can be advantageous therapeutically.

The aims of this

strategy are to decrease the dosage of mimics needed to achieve e↵ective gene
modulation and minimize unwanted toxicity. The data support that ligand-targeted
delivery of nigericin into endosomes can facilitate the escape of RNA cargo (e.g.
miRNAs, siRNAs) from their entrapping endosomes, helping the small RNAs to
become available in the cytoplasm, engage the RNA-Induced Silencing complex
(RISC) and improve their RNAi activity. Thus, it is possible that with the help of
nigericin, therapeutically relevant small RNAs could be delivered at low quantities
and still show e↵ective targeting.

The most clinically advanced ligand-siRNAs,

GalNAcsiRNA conjugates [125, 114, 143, 153, 51], have shown mixed results and
often require very high doses to achieve a signiﬁcant biological e↵ect. It is too early
to know if the high doses of these oligonucleotides will have deleterious e↵ects in the
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patients. Perhaps, achieving lower e↵ective doses of therapeutic RNAs could be the
key to avoid in vivo toxicity.
We anticipate that since nigericin is a small molecule, nontoxic, and easy to
conjugate to a small RNA using a variety of self-cleavable linkers it will be easy to
translate into the clinic. The challenge of the ﬁeld of small RNA delivery is to
continue to design and optimize delivery mechanism at all stages, from the delivery
process, to cytosolic release, to uptake into RISC and mRNA cleavage such that
small RNAs can be delivered to the intended tissues at low e↵ective doses in the
absence of unwanted toxicity. There is scientiﬁc awareness about the potential of
miRNA therapeutics, but with the lack of e↵ective cytosolic release strategies small
RNA therapeutics are predetermined to bottleneck in the clinic. Although these
molecules have yet to reach in vivo experiments, the rigorous understanding of the
safety and efficacy proﬁles of this new delivery and release platform could eventually
enable the transition of ligand-RNA conjugates from the bench to the bedside.
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4. MIRNA COMBINATORIAL THERAPEUTICS
4.1

Introduction
Lung cancer is responsible for more than 27% of all cancer related deaths in

the U.S. In 2018 alone it is estimated that ⇠154,000 patients will fall victim to
this disease (small cell (13%) or non- small cell lung carcinoma (84%, NSCLC))
[3]. This can be attributed to late diagnosis, lack of e↵ective therapeutics for latestage disease, and development of drug resistance. Due to the high mortality rate
e↵orts to search for better treatment options for cancer have been a priority and
as a result new alternative therapies have emerged. For instance, clinically relevant
tumor suppressive microRNAs (miRNAs) that target key oncogenic drivers have been
identiﬁed as potential therapeutics to treat cancer [132].
MiRNAs are small non-coding RNAs that negatively regulate gene expression at
the posttranscriptional level [92, 184, 146].

MiRNA biogenesis begins with the

transcription of a primary transcript (pri-miRNA) mainly by RNA polymerase II
[95]. This transcript resembles mRNA in that it is 50 capped and 30 polyadenylated
[95].The pri-miRNAs undergo a ﬁrst round of cleavage generating a shorter
precursor miRNA transcript (pre-miRNA, ⇠85 bp) with a stemloop structure in a
process that is mediated by the microprocessor complex (DGCR8 and type III
RNAse Drosha) [94]. Next, pre-miRNAs are transported into the cytoplasm by the
Exportin 5 [106] complex where Dicer, another RNAse III enzyme, further cleaves
the precursor transcript into a ⇠2022-nucleotide mature miRNA duplex [57, 70].
The miRNA duplex is unwound and the guide strand is incorporated into the
RNA-induced silencing complex (RISC) thus guiding RISC to a target mRNA based
on incomplete base-pair complementarity. Generally, the miRNA target speciﬁcity
is determined based on sequence pairing of the 50 end of the miRNA, particularly
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nucleotides 2-8 (seed sequence), to an incomplete complementary sequence located
in the mRNA (often found in the 30 untranslated region (UTR)) [97]. However,
recent studies suggest seed-independent binding [67], thus bioinformatic prediction
of miRNA targets tends to be complex and experimental approaches are used
instead.
MiRNA aberrant expression is a hallmark of cancer and is supported by strong
evidence [132].

It has been shown that aberrant miRNA expression, through

misexpression of miRNA target genes, can have profound cellular e↵ects leading to a
variety of diseases, including cancer [97, 109, 168, 198].

For instance, the

chromosomal region (13q14) is often deleted in patients with B cell chronic
lymphocytic leukemia (B-CLL) and harbors two tumor suppressive miRNA genes,
miR-15a and miR-16-1 [19], that can negatively regulate the antiapoptotic B cell
lymphoma 2 gene (Bcl2 ) causing CLL cells to undergo apoptosis [35]. The opposite
is also true where a miRNA can be overexpressed and contribute to cancer
development and progression. For instance overexpression of the miR-17⇠92 cluster,
often overexpressed in patients with B-CLL, can enhance lymphoma in mouse
models [65]. miRNA’s expression can be altered by various mechanisms including
genetic alterations [18], oncogene- and tumor suppressor-mediated transcription
[127, 9], epigenetic mechanisms [149, 102] and biogenesis defects [118, 68].
Depending on the status and function of an speciﬁc misregulated miRNA, a
therapeutic strategy could be separated into two main classes:
replacement.

inhibition or

MiRNA inhibition is the approach that has advanced faster

therapeutically. The idea is to inhibit an overexpressed miRNA using a chemically
stabilized oligonucleotide complementary to the miRNA as ﬁrst exempliﬁed by the
inhibition of let-7 by introduction of a 20 -O-methyl oligo [71].

Theese miRNA

antagonists have been termed antagomiRs and are routinely used to block miRNA
activity. MiRNA replacement therapeutics, on the other hand, aim to restore the
expression of a miRNA that has been lost or downregulated in a cell, and have
shown to o↵er therapeutic beneﬁts [183, 171, 77]. One of approach that is clinically
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feasible to achieve miRNA restoration is the use of miRNA synthetic analogues that
mimic mature miRNAs (hence their name, mimics) and obviate the need to use the
endogenous miRNA biogenesis machinery. For example, restoration of miRNA-34a
(miR-34a), a tumor suppressor miRNA that is a direct transcriptional target of p53
[9, 24, 66] and thus is reduced in p53 mutant tumors, has clear e↵ects on cell
proliferation and survival in murine models of cancer [76].
It has been shown that miRNA replacement therapies could be used in
combination with other agents to simultaneously target multiple genes to improve
therapeutic response [76, 187]. Since miRNAs can regulate multiple gene targets
[97, 109] it is possible that two or more miRNAs could potentially collaborate to
repress the expression of numerous cancer-related genes in various pathways. Our
lab and others have showed that it is possible to combine two small RNAs to
enhance the therapeutic response [76, 187]. For instance, we showed that miR-34a
can synergize with let-7b, another tumor suppressive miRNA that targets Kras [76].
Thus, we reasoned that other miRNA combinations could potentially collaborate to
repress the expression of multiple cancer-related genes a↵ecting multiple pathways,
and thus further improving therapeutic responses.
Herein, we used an unbiased approach to identify combinatorial miRNA pairs
with enhanced efficacy for lung cancer in cell-based studies. This approach allowed
us to identify a subset of miRNAs that was able to enhance miR-34a antiproliferative
activity. Our evaluation of the top candidate pairs showed that they have a synergistic
interaction. We show that miRNA combinatorial therapeutics could o↵er superior
tumor-suppressive abilities to suppress oncogenic properties compared to a monotherapeutic approach. We propose that by targeting multiple oncogenic drivers at
the same time with miRNA combinations that act synergistically, the development
of drug resistance is less likely due to the accumulation of mutations in tumors.
The next logical step is to understand the mechanism of action of the miRNA
combinations.

Because little is known about how these miRNAs function, we

proposed to identify their gene targets experimentally. One of the biggest challenges
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of the protocols to generate miRNA target-chimeras in order to identify potential
targets is the low efficiency of ligation reactions.

In CLASH, PAR-CLIP and

CLEAR-CLIP the addition of an ectopic ligase to a lysate increased the number of
chimeras from 0.2% to 2% (5% in some instances for CLEAR-CLIP) [58, 14, 122], so
we reasoned that the expression of an RNA ligase in vivo could increase the number
of chimeras.

We have developed a method that allows for the formation and

enrichment of miRNA-RNA chimeras that we have termed In vivo Ligation and
Sequencing of Hybrids (iLASH). This method could help to identify endogenous
targets of miRNAs and shed light into the biological mechanism of the miRNA
combinations.

4.2

Materials and Methods

4.2.1

Cell culture

A panel of six non-small cell lung cancer (NSCLC) cell lines: H441, A549,
EKVX, Calu6, H460 and H23, mycoplasma-free as determined by testing for
mycoplasma contamination via MycoAlert Mycoplasma Detection Kit (Lonza), were
grown in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal
bovine serum (Sigma), penicillin (100 U/ml ), and streptomycin (100 g/ml)
(HyClone, GE Healthcare Life Sciences), and maintained at 37 C in 5% CO2 .
Authentication of cell lines was performed using short tandem repeat proﬁling
[American Type Culture Collection (ATCC)].

4.2.2

H441-pmiR cell line generation for measuring transfection e�ciency

H441 cells were transfected with pmiR-Glo plasmid (Promega) and stable clones
(H441 pmiR) were isolated after G418 antibiotic (Corning) selection. Stable clones
were grown in RPMI 1640 medium (Life Technologies) supplemented with G418
(300ug/mL), 10% fetal bovine serum (Sigma), penicillin (100 U/ml ), and

96
streptomycin (100 g/ml) (HyClone, GE Healthcare Life Sciences), and maintained
at 37 C in 5% CO2 . H441-pmiR clones were screened for luciferase activity using
the Dual Glo Luciferase Assay (Promega) following the instructions of the
manufacturer (Figure 4.1A,B). Luciferase signal was measured in a GloMax plate
reader (Promega). Fireﬂy luciferase is used as a measurement of the transfection
efficiency when cells are co-transfected with a siRNA against ﬁreﬂy luciferase
(siLuc2) and it is calculated as a percentage of ﬁreﬂy activity in untreated cells.
Wells with <90% were excluded from analyses. Renilla activity serves as a proxy for
cell number (Figure 4.2).

Fig. 4.1. Generation of H441-pmiR cells. Single clones of H441
cells stably expressing pmiR-Glo plasmid (Promega). Clones were
evaluated for ﬁreﬂy and renilla activity. Clone 22 was selected for
screenings. Error bars: mean ± s.d., n=6

4.2.3

miR-34a dose response studies

Transfections with miR-34a were performed to determine the dose of mimic to be
used in the screening. Transfections were performed in 384-well plates using a reverse
transfection protocol with Lipofectamine RNAimax (Invitrogen) using the following
concentrations : 0.5, 1.5, 3, 6, 12 and 25 nM. A scrambled RNA was used as a negative
control (PremiR-NC2, Ambion, see Figure 4.3 for control selection). Each transfection
was supplemented with negative control to a ﬁnal concentration of 25 nM. Brieﬂy,
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Fig. 4.2. Using a dual luciferase expression vector to evaluate
transfection efficiency and cell number. The scheme shows a model in
which ﬁreﬂy luciferase is used as a measurement of the transfection
efficiency when cells are co-transfected with a siRNA against ﬁreﬂy
luciferase (siLuc2) and a miRNA. Renilla activity serves as a proxy
for cell number and its activity is only a↵ected when a miRNA that
alters cell proliferation is transfected.

miRNA mimics were diluted in serum free medium (SFM) to ﬁnal volume of 5 uL
(per well). In a separate tube, 0.05 uL of Lipofectamine RNAimax (Invitrogen) were
added to SFM to a ﬁnal volume of 5 uL (per well). Next, 5 uL of the miRNA mix
and 5 uL of Lipofectamine RNAimax (Invitrogen) solution were mixed and incubated
at room temperature for 30 minutes. H441 cells were harvested and cell solution was
adjusted to 4x104 cells/mL. Ten microliters of the miRNA/Lipid cocktail were added
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to the bottom of the wells of a 384-well plate (six wells per treatment). Next, 10 uL
of the cell suspension was added to each well (20 uL/well ﬁnal total volume). Plates
were incubated at 37 C with 5% CO2 for ﬁve days. On day ﬁve, cell proliferation was
evaluated using luciferase signal as a proxy for cell number as described previously.

Fig. 4.3. Selection of RNA negative control for the screening. Cell
proliferation measured with suforhodamine B (SRB) assay. Error
bars: mean ± s.d., n=6. Statistical analysis performed with one-way
ANOVA with post hoc Bonferroni correction, (ns, not signiﬁcant)

4.2.4

miRNA library screening

The human mirVana miRNA Library(Invitrogen; based on miRBase v. 21) was
used to evaluate 2,019 human encoded miRNAs in a cell-based screen. First, each
individual miRNA was assayed combined with miR-34a in equimolar concentration
(3nM each, total RNA 6 nM). Transfections were performed as previously described in
384-well plates using reverse the transfection protocol with Lipofectamine RNAimax
(Invitrogen)[131]. The following controls were included in each plate: i) miRNA being
evaluated + miR-34a (3 nM each), ii) full dose of miR-34a (6 nM), and iii) the full dose
of a scrambled miRNA control (6 nM) and iv) untreated. On day ﬁve, cell proliferation
was evaluated using luciferase signal as a proxy for cell number as described previously.
Outliers were eliminated if transfection efficiency was determined to be lower that 90%
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(Figure 4.2). Cell proliferation was normalized to negative control treated cells and
miRNA combinations were ranked according to the normalized values. To identify
putative positive hits we used ± three standard deviations of the full dose of mir-34a
(6 nM) as the threshold.

4.2.5

Secondary validation of putative hits

A secondary validation of putative hits identiﬁed from the primary screening was
performed as described above.

Cell proliferation was evaluated using the

sulforhodamine B (SRB) assay as a proxy for cell number [131] (see Figure 4.4 for
method validation). We included the following controls in each plate: miRNA being
evaluated + miR-34a (3 nM each), ii) full dose of miR-34a (6 nM), iii) the full dose
of a scrambled miRNA control (6 nM, PremiR-NC2, Ambion) and iv) the full dose
of each miRNA being evaluated (6 nM). Secondary validation was preformed using
the following panel of non-small cell lung cancer (NSCLC) cell lines: H441, A549,
EKVX, Calu6, H460 and H23. The Response Additivity approach [160] was used to
determine which miRNA combinations were better than each miRNA alone. The
approach consists in showing that the e↵ect of a positive miRNA combination
occurs when the combination e↵ect (Epair ) is greater than the expected additive
e↵ect

given

by

the

sum

(Combinatorial index(CI) = EmiR

34a

of

the

+ EmiR

X /Epair )

individual
[52].

e↵ects

The statistical

signiﬁcance is then given by the P-value (↵=0.05) of the Student’s T test comparing
the miRNA combination e↵ect to the e↵ect of miR-34a as a single agent. Since this
approach provides limited evidence of synergy, additional experiments evaluating
cell proliferation of H441 cells transfected with di↵erent concentrations of the
miRNA combination and the individual miRNAs.

Transfections with miRNA

candidates were performed in 384-well plates with constant ratio 1:1 (miR-34a +
miR-X) using the following concentrations :

0.5, 0.75, 1.5, and 3 nM. Each

transfection was supplemented with negative control to a ﬁnal concentration of 6
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nM. Synergism was evaluated using Combosyn software (Combosyn) based on the
combination index (CI)-isobologram equation [33]. The equation helps to gain a
better understanding of drug interactions, where CI < 1 indicate synergism, CI = 1
indicate additive e↵ect, and CI > 1 indicate antagonism [33].

Fig. 4.4. Validation of suforhodamine B (SRB) method for secondary
veriﬁcation of screen hits. A) Absorbance of SRB as a linear response
to H441-pmiR cell number. Error bars: mean ± s.d., n=6. B)
Response of H441-pmiR to miR-34a measured by SRB. Error bars:
mean ± s.d., n=6

4.2.6

T4 RNA Ligase 1 cloning

In order to understand the mechanism of action of the miRNA combinations
we proposed to identify their gene targets experimentally. MiRNA target-chimeras
have been shown to occur endogenously in the absence of biochemical methods to
catalyze RNA-RNA ligations [58, 14, 122]. We reasoned that the overexpression of
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an RNA ligase (i.e. the bacteriophage T4 RNA Ligase 1 - T4rnl1) could mediate the
formation of RNA hybrids and enrich for miRNA target-chimeras. To overexpress T4
RNA Ligase 1 (T4rnl1) in mammalian cells pCDNA3-T4rnl1 plasmids (Figure 4.5)
were constructed by Polymerase Chain Reaction (PCR) ampliﬁcation from pKH13t4rnl1 parental plasmids [62] followed by restriction enzyme treatment and T4 DNA
ligation. pKH13-t4rnl1 parental plasmids were a kind gift from Dr. Kook Han from
Dr. Stephen Lory’s laboratory. The oligonucleotides and plasmids used in plasmid
construction are listed in Tables 4.1 and 4.2 respectively. To construct plasmids
pCDNA3-T4rnl1, plasmid pCDNA 3 (Invitrogen) was used as the backbone. Two
restriction enzyme (RE) sites were introduced by PCR at the ends of the T4rnl1
amplicon. A Kozack sequence was introduced in the forward primer as well as a
HindIII RE site. The reverse primer included a KpnI RE site, a six histidine tag
(6Xhis) and a stop codon. T4rnl1 amplicons and pCDNA 3 backbone plasmid were
digested with HindIII and KpnI restriction enzymes, ligated using T4 DNA ligase and
transformed into NEB5↵ (New england Biolabs). Cloning orientation was conﬁrmed
by sequencing. Three new constructs were generated: pCDNA3-T4rnl1-WT (Wild
type), pCDNA3-T4rnl1-K (K99N single mutant), and pCDNA3-T4rnl1-KE (K99N,
E159A double mutant).
Table 4.1.
T4 RNA Ligase 1 primer list
Primer

Sequence

Use

T4rnl1 F

CAACGTAAAGCTTATGCAAGAACTTTTTAACAATTTA

Cloning

T4rnl1 R

CAACGTAGCCGGTACCTAGTGATGGTGATGGTGATGGTATCCTTCTGGGATAA

Cloning

T4rnl1 F q

CTCAGATGATGTAAGTGCATCTGGAAG

qrtPCR for T4rnl1

T4rnl1 R q

CATAATTCCACGACATTCTAGTGCATC

qrtPCR for T4rnl1
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Fig. 4.5. Map of pCDNA3-T4rnl1 plasmids. Plasmid graphics from
PlasMapper Version 2.0.

Table 4.2.
T4 RNA Ligase Plasmids
Plasmid

4.2.7

Source

pKH13-t4rnl1-WT

Han et al., 2016

pKH13-t4rnl1-K99N

Han et al., 2016

pKH13-t4rnl1-K99N E159A

Han et al., 2016

pCDNA3-T4rnl1-WT

This study

pCDNA3-T4rnl1-K

This study

pCDNA3-T4rnl1-KE

This study

T4 RNA Ligase 1 overexpression and capture of hybrids

To overexpress T4 RNA Ligase 1 (T4rnl1) in mammalian cells pCDNA3-T4rnl1
plasmids were transfected into H441 NSCLC cells using Lipofectamine 2000
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(Invitrogen) in 6-well plates (3 wells per treatment). Brieﬂy, H441 cells were seeded
into 6-well plates at a density of 7x105 cells/well and incubated at 37 C with 5%
CO2 . The next day, 2.5 ug of each plasmid and 6 nM of miRNA mimic were diluted
with serum free medium (SFM) to a ﬁnal volume of 100 uL (per well).
Lipofectamine 2000 (6 uL, Invitrogen) was added to 94 uL of SFM. Next, 100 uL of
the plasmid solution was mixed with 100 uL of the Lipofectamine 2000 (Invitrogen)
mixture and incubated at room temperature for 30 minutes. Each well was rinsed
once with phosphate bu↵ered Saline (PBS, pH 7.4) and 800 uL of complete medium
was added into each well. The nucleic acid/lipid cocktail (200 uL) was dripped into
each well and the cells were incubated at 37 C with 5% CO2 for four hours before
medium was replaced with 2 mL of complete medium. After 24 hours total RNA
was isolated from each well group (3 per treatment) using the Direct-zol RNA mini
prep kit (Zymo) following the manufacturer’s instructions. RNA concentration was
quantiﬁed using Nanodrop (Thermo Scientiﬁc) and quality was assessed using an
RNA Eukaryote Pico Chip (Agilent).

Evaluation of chimera formation was

performed by PCR using the Chimera PCR (ChimP) method [14].

Further

veriﬁcation was performed by sequencing of PCR products previously cloned by
TOPO-TA cloning (Invitrogen).

4.3

Results

4.3.1

Cell line generation and response to miR-34a

First, we determined that when the dose of miR-34a transfected into H441 cells
exceeded 6 nM there was no further reduction in cell proliferation (Figure 4.6A). Thus,
we elected to use 6 nM as our highest dose. Due to the nature of the screening and the
fact that transfection efficiency plays an important role in the results, we decided to
generate a tool that would allow us to to determine the transfection efficiency in every
well. For that purpose, we generated a clone of H441 cells stably expressing a pmiRGlo plasmid (Promega, H441-pmiR) that expresses both renilla and ﬁreﬂy luciferase.
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We ﬁrst determined that renilla and ﬁreﬂy activity correlate with cell number (Figure
4.6B,C) and that low doses of siRNA against luciferase (siLuc2) cause a signiﬁcant
decrease in ﬁreﬂy activity (Figure 4.6D). Thus we elected to use 0.5 nM of siLuc2
co-transfected with every miRNA combination. We decided to use ﬁreﬂy luciferase as
a measurement of the transfection efficiency (Figure 4.6E) measured as a percentage
of ﬁreﬂy repression compared to untreated cells. Renilla activity was used as a proxy
for cell number (Figure 4.6F). In accordance with our model in Figure 4.2, the data
show that reduction in renilla activity is only observed when a miRNA that a↵ects
cell proliferation is present (i.e. mir-34a, Figure 4.6F).

4.3.2

Screening results

We used miR-34a as a model to identify and validate miRNAs that enhance its
antiproliferative activity in cell-based assays using an unbiased approach combining
miR-34a individually with 2,019 human encoded miRNAs mimics. For this, we
screened the antiproliferative activity of the miRNA combination in H441-pmiR
cells. The results of the primary screening show that there is a subset of miRNAs
that when combined with miR-34a have decreased cell proliferation levels compared
to mir-34a alone (6nM, Figure 4.7A). Since, the 6nM dose of each miRNA of the
library was not included in the primary screening we decided to re-evaluate the
miRNA combinations that fell below 3 standard deviations of the e↵ect achieved by
miR-34a alone (6nM, 333 combinations).

For that reason, we tested each

combination with miR-34a (3nM each) and the miRNA candidates alone (6 nM)
and reasoned that a positive hit would be a miRNA combination that had better
antiproliferative activity than the miRNA being tested on its own (111 miRNA
pairs, Figure 4.7B). To provide further evidence of the superiority of the miRNA
combination compared to its single agents we used additional functional assays to
test 111 miRNA pairs in a panel of six NSCLC cell lines (H441, A549, EKVX,
Calu6, H460, H23). We used the Response Additivity approach [160] to determine
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Fig. 4.6. Evaluation of miR-34a e↵ect in H441-pmiR cells.A) miR34a dose response in H441-pmiR cells. Error bars: mean ± s.d. Each
experiment corresponds to n=8 per treatment. Statistical analysis
performed with two-way ANOVA with post hoc Bonferroni correction,
(***, P < 0.001). B) Renilla and C) Fireﬂy luciferase activity linear
response to cell number (Error bars: mean ± s.d., n=6). D) Fireﬂy
luciferase repression upon transfection with siLuc2. Error bars: mean
± s.d. Each experiment corresponds to n=6 per treatment E) Fireﬂy
and F) renilla activity upon transfection of miR-34a or PremiR-NC2
in presence of siLuc2. Error bars: mean ± s.d. Each experiment
corresponds to n=6 per treatment. Statistical analysis for B, C, D, E
and F performed with a one-way ANOVA with post hoc Bonferroni
correction, (*, P < 0.05; **, P < 0.01; ****, P < 0.0001).
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which miRNA combinations were better than each miRNA alone and compared the
lists of miRNA combinations that had a CI lower than 1, p < 0.05 and that the
normalized proliferation value for the miRNA being tested alone was not > 1. We
then compared the lists of miRNAs obtained from each NSCLC cell line and
identiﬁed 12 miRNA combinations that enhanced miR-34a e↵ect in at least 4
di↵erent cell lines (Figure 4.7C, the list of miRNAs can be found in the Appendix
section). Next, we further evaluated the top 12 miRNA combinations by assessing
the potencies of both miRNAs, and characterized the possible existence of
synergistic or antagonistic e↵ects. Our data shows that there are six miRNAs that
show higher antiproliferative activity when combined with miR-34a: miR-6715b,
miR-4664-3p,

miR-3157-3p,

miR-5100 and let-7a-2-3p (Figure 4.8A-E). In

agreement with this observation, the CI values for these combinations is < 1, thus
suggesting the possibility of a synergistic interaction (Figure 4.8F).

4.3.3

Identiﬁcation of the biological mechanism

The next logical step was to understand the mechanism of action of the miRNA
combinations. Because very little is known about how these miRNAs function we
proposed to identify their gene targets experimentally. For that reason, we have
developed a method that allows for the formation of miRNA-RNA chimeras that
could shed light on the identity of their endogenous targets. The method takes
advantage of the observation that cross-linking immunoprecipitation (CLIP-Seq)
and photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation
(PAR-CLIP) sequencing libraries often contain chimeric reads even in the absence of
biochemical methods to generate chimeras, suggesting that an endogenous ligase
could catalyze this reaction [58, 14]. Thus, we reasoned that formation of chimeras
could be enhanced by overexpression of an exogenous RNA ligase. A recent study
reports the formation of RNA chimeras in bacteria by overexperession of the
bacteriophage T4 RNA ligase 1 (T4rnl1) [62].
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Fig. 4.7. miRNAs alter miR-34a antiproliferative potential. A)
miRNA mimics ranked according to cell number normalized to
negative control (NC) transfected cells. Red dashed line= 3 s.d. of the
e↵ect of miR-34a alone. Black dashed line= E↵ect of NC treated cells.
Blue shaded box= 333 miRNA mimics. N= 6. Each dot represent
the mean e↵ect of a miRNA combination. B) Secondary validation of
111 miRNA mimics represented as the e↵ect of the individual e↵ect
of the miRNA (Esingle ) minus the e↵ect of the combination with miR34a (Epair ). Values < 0 indicate miRNA pairs that show a better
aniproliferative activity than the miRNA individual e↵ect. N= 6.
Each dot represent the mean e↵ect of a miRNA combination. Orange
shaded box = 111 miRNA mimics. C) miRNA evaluation in a panel
of six NSCLC cell lines. miRNAs included in this comparison had a
CI lower than 1 (potential synergism), p < 0.05 and cell proliferation
of the single miRNA was < 1.
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Fig. 4.8. Evaluation of synergism of positive hits. The possibility
of synergism was evaluated in A) miR-6715b, B) miR-4664-3p, C)
miR-3157-3p, D) miR-5100 and E) let-7a-2-3p. miRNA combinations
have a stronger e↵ect than each miRNA on its own. F) Evaluation of
synergism using the (CI)-isobologram equation. The equation helps
to gain a better understanding of drug interactions, where CI <
1 indicate synergism. Statistical analysis performed with one-way
ANOVA with post hoc Bonferroni correction, ( ***, P < 0.001; ****,
P < 0.0001).
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T4rnl1 is able to catalyze the ligation between a 50 monophosphorylated donor to
a 30 hydroxyl-terminated nucleic acid. T4rnl1 join 30 OH and 50 P O4 RNA termini
via a three step reaction: in the ﬁrst step the RNA ligase reacts with ATP to form
a ligase-(lysyl-N)AMP intermediate plus pyrophosphate; in the second step AMP
is transferred to the 50 monophosphorylated RNA end to form an RNA-adenylate
intermediate (AppRNA); and ﬁnally the ligase catalyzes the attack by an RNA 30
hydroxil on the RNA-adenylate forming a phosphodiester bond [157, 180]. Mutation
of lysine 99 in T4Rnl1 has been shown to inactivate the enzyme in all three steps
of the ligation reaction [157, 180]. Similarly, mutations in glutamic acid 159 also
abrogate RNA sealing activity in vitro [181]. Thus, T4rnl1 mutants could be used as
negative controls.
While most mammalian newly synthesized RNAs bear a triphosphate on their 50
end (later the distal phosphate is replaced by an inverted methylated GMP), RNAs
that are undergoing mRNA decay undergo hydrolysis of the cap to a 50
monophosphate that in theory, would serve as a 50 PO4 RNA donor for ligation
mediated by T4rnl1. It has been shown that mRNA decaping can be triggered by
miRNAs and that microRNA-directed cleavage can also generate a 30 product with
a ligation-competent 50 monophosphate [192, 101]. Furthermore, mature miRNAs
themselves could serve as a substrate for ligation, without further modiﬁcation,
since it is believed that mature miRNAs require a 50 monophosphate to be loaded
into Argonaute [70]. Exploiting the fact that miRNA-mRNA interaction require
base-pairing, we reasoned that expresion of a T4rnl1 transgene would lead to
ligation between the 50 monophosphate of the miRNA, the decaying mRNA or
cleaved mRNA, and the 30 hydroxyl end of miRNAs or mRNAs. To test this we
generated the following T4rnl1 constructs in a mammalian expression vector:
T4rnl1-WT

(Wild

type),

pCDNA3-T4rnl1-K

(K99N

single

mutant),

and

pCDNA3-T4rnl1-KE (K99N, E159A double mutant), and hypothesized that
miRNA-RNA chimeras will be enriched in cells expressing T4rnl1 WT. First, we
evaluated the expression of T4rnl1 in H441 cells by RT-qPCR (Figure 4.9A) and
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assessed the e↵ect of expression of T4rnl1 on cell growth (Figure 4.9B). The data
shows that H441 cells continued to grow for at least 24 h, followed by a decline in
cell proliferation that is only present in cells transfected with the wild type form of
T4rnl1 (Figure 4.9B). For each experiment, H441 cells were incubated for 24 hours
after plasmid transfection. To evaluate if the expression of T4rnl1 is able to generate
miRNA-chimeras, we selected the tumor suppressor candidate 2 gene (TUSC2) that
is a known gene target of the let-7 miRNA family [186] and evaluated the formation
of let-7 -TUSC2 chimeras by chimera PCR (ChimP) method [14]. Our results show
that chimera formation was only detectable in T4rnl1 WT treated cells (Figure
4.9C). Moreover, the sequencing results of the putative let-7 -TUSC2 chimera show
that the 50 end of TUSC2 was ligated to the 30 end of let-7-c (Figure 4.9D)
approximately 200 bp downstream of the reported miRNA response element of
let-7-c in the 30 UTR of TUSC2 (Figure 4.9E). This preliminary evidence suggests
that T4rnl1 could be used for identiﬁcation of unknown targets of mirNAs.

4.4

Discussion and future directions
The results of this study show that miRNA combinatorial therapeutics could o↵er

superior tumor-suppressive abilities to suppress oncogenic processes in lung cancer
compared to a mono-therapeutic approach. The combination of our top six candidate
miRNAs with miR-34a was able to enhance miR-34a antiproliferative activity and
further reduce cell proliferation. Our evaluation of these six candidate pairs showed
that they have a synergistic interaction, meaning that the combination works better
that each miRNA as a single agent. It is likely that these miRNA combinations could
be used clinically in scenarios in which monotherapies often develop drug resistance
due to the accumulation of mutations in tumors. We propose that targeting multiple
oncogenic drivers with miRNAs that act synergistically could be beneﬁcial to cancer
therapy avoiding the development of resistance.
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Fig. 4.9. Generation of miRNA-RNA chimeras in vivo. A) Expression
of T4 RNA ligase 1 (T4rnl1) in H441 cells. UT: untreated, EV: empty
vector, ND: Not detected, SD: standard deviation. B) E↵ect of T4rnl1
expression in H441 cell growth. Statistical analysis performed with
two-way ANOVA with post hoc Bonferroni correction, ( **, P < 0.01).
C) Detection of miRNA-RNA chimera using Chimera PCR. miRNA:
Let-7c-5p, RNA: TUSC2 gene. * primers band. D) sequence of Let7 /TUSC2 chimera. E) Position of the ligation event relative to Let7c-5p target site (TS) in the 30 untransladed region (UTR) of TUSC2.
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While this study shows that there are miRNAs that could be used in combination
with miR-34a to enhance antiproliferation abilities in cell-based studies, further in
vivo validation will be required, particularly focused on a comparison between the
monotherapies and the combinatorial miRNA therapeutics. One possibility for these
types of studies could be the use of the Kras/p53 mouse model used in the studies in
chapter 2. Due to the fact that some of these miRNA candidates are reported to be
the passenger strand, a transgene overexpression approach (viral delivery for instance)
would not be feasible since it would require processing of the pre-miRNA into the
mature form and there is no guarantee that the right strand would be loaded into
the RNA induced silencing complex (RISC). Perhaps an approach using chemically
synthesized and modiﬁed miRNA mimics would be useful to ensure delivery as well
as loading of the correct strand into RISC. The FolamiR platform [134], for instance,
along with chemical modiﬁcations to the miRNA mimics would allow loading of the
correct strand into RISC could help circumvent this issue and deliver these miRNAs
into Kras/p53 tumors in vivo.
The next step is to identify the biological mechanism by which these miRNAs
are able to a↵ect cell growth.

To achieve this goal several methods have been

developed (CLASH [67], iPAR-CLIP[58]), CLEAR-CLIP[123] to identify targets of
miRNAS using immunoprecipitation of Argonaut proteins crosslinked to transcripts.
Although, these strategies have been shown to work for identiﬁcation of targets of
endogenous miRNAs, little is known of their use in the case of replacement of
miRNAs using synthetic mimics. One problem of trying to use these approaches to
identify miRNA mimic targets is that only Argonaute 2 is able to unwind and use
miRNA mimics as guides because the passenger and guide strands in miRNA
mimics are designed to be 100% complementary to each other and thus resemble
siRNAs [194]. For that reason we proposed to use a strategy that does not require
the use of Argonaute immunoprecipitation and uses T4rnl1 to ligate miRNAs to
their putative targets in vivo.

This approach could be used to enrich for

miRNA-RNA chimeras that could be used to identify potential endogenous miRNA
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targets. The understanding of the biological mechanism could shed light on possible
drug combinations (besides miRNAs) that could be used with miR-34a to further
improve the therapeutic response.
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5. DISCUSSION AND FUTURE DIRECTIONS
miRNA mimics are exceptional maleable molecules that could be used to combat
many diseases, including cancer. The studies presented in this dissertation speciﬁcally
seek to explore strategies to enhance miRNA-based therapeutics and delivery, and to
use this understanding to develop cancer treatments. We ﬁrst show that it is possible
to deliver a therapeutically relevant miRNA mimic by conjugating it to a targeting
ligand that will bind to a receptor that is overexpressed on cancerous cells. Next,
we show that by including an endosomal escape mechanism into the ligand carrier, it
is possible to avoid entrapment which is a major limitation in the targeting delivery
ﬁeld. Finally, we show that miRNA combinatorial therapeutics could o↵er superior
tumor-suppressive abilities to suppress oncogenic properties compared to a monotherapeutic approach. Although the experiments have yet to reach humans, it is
plausible that these approaches could help reduce unwanted toxicity along two lines
simultaneously: i) speciﬁcity of uptake and cytoplasmatic release, and ii) targeting
multiple key oncogenic factors, both of which could be important to achieve a reduced
e↵ective dose in the absence of unwanted toxicity to treat cancer. To be e↵ective
clinically, these molecules must be optimized at all stages including delivery, ligandreceptor recognition, trafficking into the cytoplasm, loading into RISC and recognition
of mRNA target. This chapter focuses on ways that could help to further optimize the
therapeutic potential of miRNA mimics and other potential uses of ligand-mediated
delivery of RNA.

5.1

Tailoring the ligand and small RNA cargo
Developing a highly speciﬁc delivery platform with increased endosomolytical

properties could be useful to translate RNA therapeutics into the clinic by helping
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to achieve signiﬁcant therapeutic e↵ects at low concentrations and without
unwanted toxicity (Figure 5.1). The targeting ligand itself could be tailored to an
speciﬁc receptor that is overexpressed in the cell membrane of a particular cancer
type. For instance, the prostate-speciﬁc membrane antigen (PSMA, also knowns as
FOLH1) is a cell-surface enzyme that is overexpressed in prostate cancers, but
minimally present in healthy tissues [55]. PSMA can undergo cellular internalization
through clathrin-coated pits and recycle rapidly to the cell surface for additional
rounds of uptake [98]. The targeting ligand 2 - [ 3 - ( 1, 3 - dicarboxypropyl ) ureido
] pentanedioic acid (DUPA) is one of the small molecular ligands of PSMA with
highest affinity and has been used for cancer imaging purposes by attaching
ﬂuorescent reporters [83]. Our preliminary evidence shows that DUPA can be used
to deliver functional miR-34a mimics into LNCaP cells (prostate cancer) in culture
(Figure 5.2A) and that internalization of the conjugates is dependent on PSMA
(Figure 5.2B). Due to the heterogeneous nature of the tumor, it would be beneﬁcial
to investigate if other receptors could be used to deliver small RNAs into the tumors
and perhaps if multiple ligands could be used in combination to deliver multiple
RNA cargo simultaneously without competition.
The second option is to tailor the small RNA attached to the ligand carrier.
For instance, cytotoxic or pro-apoptotic RNAs could be used instead of cytostatic
miRNAs (i.e. miR-34a). The advantage of using siRNAs instead of miRNAs is that
in theory they have a single endogenous gene target and are usually considered a
good strategy to target genes that are difficult to drug. There are di↵erent genes
that could be targeted with siRNAs including, the anti apoptotic B-cell lymphoma
2 (BCL2), the oncogene KRAS, polo-like kinase 1 (PLK-1), and cyclin B1, among
others. Another strategy could be the activation of the immune system by targeting
proteins like the programmed death-ligand 1 (PD-L1) in cancer cells.
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Fig. 5.1. Ligand mediated miRNA replacement therapy. LigandmiRNAs enter circulation (1), localize to target tissue (2), get
internalized into target cells via ligand receptors and escape the
endosome (3), and excess ligand-RNA gets excreted from the body
(4) avoiding unwanted toxicity. Modiﬁed from Orellana and Kasinski,
2017. Oncotarget, in accordance with the Creative Commons
Attributions Unported 3.0. license.

5.2

Optimization of miRNA mimic chemical modiﬁcations and sequence
MiRNA activity and pharmacokinetic properties can to some extent be

optimized by modifying the chemical modiﬁcations that stabilize the ribose
backbone. The same chemical modiﬁcations that have been used for siRNAs can
also be applied to miRNA mimics. Particularly, replacement of ribonucleotides with
20 -O-Methyl (20 -O-Me) nucleotides in the passenger strand has proven useful to
make the oligonucleotides more stable to nucleases without a↵ecting too much
target recognition. The modiﬁcation pattern of the passenger strand often include
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Fig. 5.2. DUPA-mediated delivery of miRNA. A) Dose response
curve of DUPA-miR-34a conjugates. LNCaP cells stably expressing a
miR-34a Renilla sensor were incubated with di↵erent concentrations
of DUPA-mir-34a conjugates and Renilla activity was measured
after 72 h. NC: negative control miRNA. B) DUPA-miR-34a
uptake is dependent on PSMA internalization.
LNCaP cells
stably expressing a miR-34a Renilla sensor were incubated with
DUPA-RNA in the absence or presence of the competitor 4(phosphonomethyl)piperazine-2-carboxylic acid (PMPA). Error bars:
mean ± s.d. Each experiment corresponds to n=3, 4 technical
replicates per treatment, statistical analysis performed with one-way
ANOVA and Bonferroni correction, (**, P < 0.01)

20 -O-Me bases every second position. Also, these modiﬁcations can prevent incorrect
loading of the passenger strand into the RISC [79].

In the case of the mature

miRNA strand, since it must load efficiently to the RNAi machinery to function, it
is more sensitive to extensive chemical modiﬁcations. Nonetheless, lessons learned
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from siRNAs show that 20 -Fluor (20 -F), one of the best analogues of the 20 -OH
group, can be tolerated in the guide strand of siRNAs [112]. Furthermore, a fully
modiﬁed guide strand with 20 -O-Me and 20 -F modiﬁcations in alternated pattern
create a molecule that can engage RISC [25]. Perhaps, generating a fully modiﬁed
mature miRNA strand could further increase the serum tolerance observed in
FolamiRs [134] and make the mature strand more stable against intracelullar
nucleases.
Another potential modiﬁcation that can be incorporated into the mature miRNA
strand, and has not yet been tested with FolamiRs (only chemical phosphorylation
has been used), is a 50 -phosphate stabilization using E-vinyl phosphonate (50 -E-VP).
The 50 -phosphate group of the mature strand could be removed by phosphatases upon
systemic delivery, leading to accumulation of biologically inactive miRNA incapable
of loading into RISC [26]. The 50 -E-VP modiﬁcation is not suitable to removal by
phosphatases and is compatible with RISC binding [152, 141].
Furthermore, the sequence of the miRNA mimic itself can be modiﬁed so that its
target pool is more speciﬁc to a certain therapeutic goal. In the case of miR-34a,
among its targets are cell cycle proteins, anti-apoptotic proteins, genes involved in
drug resistance, and immune suppressor proteins. Since, miR-34a alone cannot cause
tumor reduction and depending on the cancer context, cause either senescence or
cell cycle arrest, its potential use as drug sensitizer is dampened since some of these
chemical agents require dividing cells to function (i.e. cisplatin). If one could modify
the sequence of miR-34a in such a way that it only targets genes involved in drug
resistance and not cell cycle proteins, the therapeutic potential of miR-34a would be
enhanced.

5.3

In vivo validation of miRNA combinations
While the studies presented in this dissertation show that there are miRNAs that

could be used in combination with miR-34a to enhance its antiproliferation abilities
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in cell-based studies and that a ligand could be used for delivery, further validation
is required focusing in in vivo studies comparing between the monotherapies and the
combinatorial miRNA therapeutics. One possibility for these types of studies could
be the use of the Kras/p53 mouse model used in the studies in chapter 2. Future
studies could focus in using the FolamiR platform [134] to deliver combination of
miRNAs into Kras/p53 tumors in vivo. The next challenge would be to identify the
biological mechanism by which these miRNAs are able to a↵ect cell growth in vivo. A
way to do that could be to use our proposed strategy using T4rnl1 to ligate miRNAs
to their putative targets in vivo by cloning T4rnl1 into a viral expression vector.

5.4

Using folate-mediated delivery with other RNAs
Although the results presented here are speciﬁc to miRNAs and siRNAs,

conjugating any relevant small RNA to achieve tissue speciﬁc uptake is likely. One
possibility, that has not yet been explored using ligands, is to deliver chemically
modiﬁed small guide RNAs (sgRNAs) for CRISPR-Cas9 gene editing [133]. This
strategy could be used as a mechanism to control gene editing in a tissue speciﬁc
manner to study gene function. For instance, ligand-sgRNAs could be used with a
Kras/Cas9 mouse model to study the role of a particular gene in the context of
KRAS activation.

Another application could be the delivery of antisense

oligonucleotides (ASOs) to tumors of a Kras/p53 mouse model to study the
functions of non-coding RNAs that work in the p53 pathway. The advantages of
delivering ASOs conjugated to a ligand would be that their biodistribution can be
controlled precisely and that these oligonucleotides can be fully modiﬁed and are
resistant to nucleases.

5.5

Closing remarks
The challenge of the miRNA therapeutics ﬁeld is to continue to design new

targeting

ligands,

optimize

endosomal

escape

mechanisms,

and

identify
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therapeutical small RNAs that could be delivered to the intended tissues at low
e↵ective doses with manageable toxicity proﬁles. There is scientiﬁc awareness about
the potential of small RNA therapeutics but more research is needed to better
understand how they function and what the risks of introducing an exogenous RNA
are.

Without that information, small RNA therapeutics are predetermined to

bottleneck in the clinic. The rigorous understanding of the safety proﬁles of these
therapies will eventually enable the transition of more RNA-based drugs from the
bench to the bedside.
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List of miRNAs that alter miR-34a antiproliferative potential
Table A.1.: miRNAs that alter miR-34a antiproliferative
potential in H441 pmiR cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-miR-31-5p

0.2511

0.1561

0.0000

0.3477

hsa-miR-6500-3p

0.2435

0.1499

0.0000

0.3487

hsa-miR-6715b-5p

0.4906

0.2734

0.0000

0.2748

hsa-miR-648

0.2149

0.1133

0.0000

0.3470

hsa-miR-2355-3p

0.2509

0.1423

0.0000

0.3423

hsa-miR-4633-3p

0.3201

0.2354

0.0000

0.3485

hsa-miR-10a-5p

0.3456

0.1312

0.0000

0.2952

hsa-miR-597-5p

0.2014

0.1448

0.0000

0.3659

hsa-miR-5009-5p

0.2087

0.2046

0.0000

0.3899

hsa-miR-4725-5p

0.5587

0.3612

0.0000

0.2708

hsa-miR-5100

0.4263

0.2434

0.0000

0.2972

hsa-miR-6503-5p

0.3281

0.2992

0.0000

0.3757

hsa-miR-610

0.5806

0.2140

0.0000

0.2091

hsa-miR-5093

1.1959

0.3337

0.0000

-0.1152

hsa-miR-4664-3p

0.3829

0.2812

0.0000

0.3365

hsa-miR-141-3p

0.2079

0.1501

0.0000

0.3653

hsa-miR-4510

0.5241

0.3694

0.0000

0.2958

hsa-miR-3155b

0.6669

0.4278

0.0000

0.2281

hsa-miR-2392

1.0085

0.9058

0.0000

-0.0353

hsa-miR-4725-3p

0.6039

0.3476

0.0001

0.2379
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hsa-miR-5591-5p

0.4026

0.3361

0.0001

0.3527

hsa-miR-4681

0.2244

0.1845

0.0001

0.3727

hsa-miR-4707-3p

0.2714

0.2351

0.0001

0.3733

hsa-let-7a-2-3p

0.2885

0.1906

0.0002

0.3445

hsa-miR-4677-5p

0.4174

0.2481

0.0003

0.3037

hsa-miR-375

1.2579

0.4021

0.0004

-0.1691

hsa-miR-5007-5p

0.7564

0.4971

0.0004

0.1899

hsa-miR-5189-5p

0.9355

0.3979

0.0007

0.0420

hsa-miR-4651

0.7376

0.4797

0.0008

0.1977

hsa-miR-4444

0.4214

0.2489

0.0009

0.3019

hsa-miR-5582-5p

0.4457

0.3826

0.0009

0.3518

hsa-miR-618

0.3948

0.3206

0.0011

0.3491

hsa-miR-4687-5p

0.4604

0.4111

0.0012

0.3591

hsa-miR-6127

0.7906

0.4774

0.0013

0.1570

hsa-miR-4493

0.2951

0.2675

0.0016

0.3771

hsa-miR-6512-3p

0.5134

0.4362

0.0017

0.3382

hsa-miR-4690-5p

0.3529

0.2812

0.0020

0.3528

hsa-miR-378b

0.9854

0.3762

0.0022

0.0092

hsa-miR-1277-3p

0.7460

0.3514

0.0025

0.1534

hsa-miR-3156-3p

0.3275

0.2598

0.0026

0.3560

hsa-miR-3129-3p

0.5565

0.5298

0.0026

0.3697

hsa-miR-5702

0.9751

0.4355

0.0028

0.0173

hsa-miR-4691-3p

0.3668

0.3263

0.0028

0.3683

hsa-miR-3200-3p

0.6183

0.3590

0.0029

0.2334

hsa-miR-380-3p

1.2662

0.2352

0.0036

-0.1364

hsa-miR-4481

2.6276

0.8658

0.0041

-4.7529

hsa-miR-378g

0.9961

0.4144

0.0048

0.0026

hsa-miR-5004-5p

1.1184

0.4557

0.0049

-0.0852
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hsa-miR-766-5p

0.6490

0.4615

0.0058

0.2554

hsa-miR-509-3p

0.4674

0.3304

0.0076

0.3117

hsa-miR-450a-2-3p

0.5246

0.3815

0.0113

0.3012

hsa-miR-508-3p

0.3607

0.3119

0.0143

0.3641

hsa-miR-3157-3p

0.8533

0.5026

0.0156

0.1156

hsa-miR-2114-5p

0.3054

0.2387

0.0169

0.3576

hsa-miR-665

0.2802

0.3113

0.0184

0.4096

hsa-miR-4768-3p

0.5726

0.4316

0.0208

0.2947

hsa-miR-4438

0.4907

0.4378

0.0226

0.3550

hsa-miR-4673

0.7329

0.4207

0.0227

0.1807

hsa-miR-4648

0.6139

0.4206

0.0249

0.2611

hsa-miR-4472

1.9197

0.7286

0.0252

-1.3280

hsa-miR-548ag

0.6015

0.3866

0.0270

0.2546

hsa-miR-5703

0.9042

0.4164

0.0310

0.0643

hsa-miR-4471

0.6263

0.4841

0.0316

0.2838

hsa-miR-4755-5p

0.5964

0.3651

0.0333

0.2491

hsa-miR-5693

0.9346

0.4671

0.0333

0.0481

hsa-miR-4643

1.2271

0.3389

0.0382

-0.1346

hsa-miR-4695-5p

0.5164

0.4535

0.0387

0.3468
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Table A.2.: miRNAs that alter miR-34a antiproliferative
potential in H358 cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-miR-4664-3p

0.2629

0.0193

0.0000

0.9218

hsa-miR-4746-3p

0.2840

0.2405

0.0000

0.9544

hsa-miR-378g

0.3324

0.3553

0.0000

0.9485

hsa-miR-6500-3p

0.3842

0.5204

0.0023

0.9935

hsa-miR-4471

0.3948

0.4253

0.0001

0.9204

hsa-miR-183-5p

0.4693

0.4514

0.0000

0.8608

hsa-miR-4699-5p

0.4719

0.2877

0.0000

0.7823

hsa-miR-4768-3p

0.4766

0.2778

0.0000

0.7741

hsa-miR-665

0.5004

0.4836

0.0002

0.8503

hsa-miR-4687-5p

0.5154

0.2569

0.0000

0.7283

hsa-miR-4725-5p

0.5157

0.3243

0.0001

0.7523

hsa-miR-4450

0.5299

0.4358

0.0001

0.7910

hsa-miR-4438

0.5392

0.5326

0.0001

0.8482

hsa-miR-3192-5p

0.5395

-0.0342

0.0000

0.6356

hsa-miR-4651

0.5404

0.4005

0.0000

0.7616

hsa-miR-5189-5p

0.5600

0.6387

0.0069

0.9412

hsa-miR-508-3p

0.5653

0.4221

0.0011

0.7481

hsa-miR-4695-5p

0.5764

0.5073

0.0007

0.7911

hsa-miR-323b-5p

0.5769

0.6637

0.0046

0.9616

hsa-miR-5702

0.5828

0.5201

0.0000

0.7945

hsa-miR-3128

0.5850

0.2945

0.0000

0.6717

hsa-miR-892b

0.5968

0.5570

0.0036

0.8120

hsa-miR-4643

0.6344

0.5466

0.0003

0.7650

hsa-let-7a-2-3p

0.6434

0.4086

0.0016

0.6628
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hsa-miR-3157-3p

0.6694

0.2087

0.0000

0.5595

hsa-miR-2114-5p

0.6721

0.5430

0.0007

0.7242

hsa-miR-4690-5p

0.6827

0.5275

0.0003

0.7005

hsa-miR-4430

0.6900

0.3106

0.0001

0.5727

hsa-miR-4783-3p

0.7358

1.0620

0.0010

-2.6588

hsa-miR-4763-3p

0.7393

0.4307

0.0010

0.5788

hsa-miR-3659

0.7515

1.0292

0.0008

-5.9455

hsa-miR-4661-5p

0.7612

0.6404

0.0048

0.7423

hsa-miR-4691-3p

0.7675

1.0910

0.0002

-1.7583

hsa-miR-4682

0.7847

1.1234

0.0008

-1.2523

hsa-miR-5703

0.7863

0.5674

0.0004

0.6324

hsa-miR-4510

0.8013

0.7087

0.0224

0.8204

hsa-miR-3607-3p

0.8137

1.0391

0.0253

-4.4468

hsa-miR-4253

0.8389

1.3548

0.0000

-0.3493

hsa-miR-378b

0.8465

1.1791

0.0005

-0.8573

hsa-miR-28-5p

0.8571

1.0782

0.0409

-2.1722

hsa-miR-2392

0.8591

0.4241

0.0002

0.4554

hsa-miR-4539

0.8698

0.3662

0.0000

0.4160

hsa-miR-4473

0.8785

0.4858

0.0131

0.4737

hsa-miR-509-3p

0.8872

0.6505

0.0441

0.6309

hsa-miR-671-3p

0.8879

0.4022

0.0000

0.4150

hsa-miR-4281

0.8953

1.3889

0.0000

-0.3610

hsa-miR-3156-3p

0.9058

0.6194

0.0258

0.5700

hsa-miR-33b-3p

0.9123

1.1548

0.0001

-1.0822

hsa-let-7c-5p

0.9272

1.0391

0.0117

-4.5630

hsa-miR-31-5p

0.9370

1.4231

0.0000

-0.3650

hsa-miR-4725-3p

0.9373

0.6356

0.0221

0.5597

hsa-miR-4700-5p

0.9464

0.6393

0.0442

0.5556
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hsa-miR-4444

0.9557

1.3976

0.0000

-0.4111

hsa-miR-1245b-5p

0.9622

0.6516

0.0151

0.5576

hsa-miR-10a-5p

0.9685

1.0180

0.0488

-10.0187

hsa-miR-4681

0.9685

1.4909

0.0225

-0.3374

hsa-miR-6089

0.9824

0.5235

0.0007

0.3977

hsa-miR-5100

0.9981

0.6074

0.0229

0.4631

hsa-miR-3130-5p

1.0368

1.2987

0.0000

-0.6430

hsa-miR-5007-5p

1.0707

0.6747

0.0397

0.4860

hsa-miR-383-5p

1.0733

1.0219

0.0143

-8.3544

hsa-miR-548ag

1.0811

0.6822

0.0243

0.4887

hsa-miR-27b-3p

1.0841

1.1838

0.0033

-1.0695
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Table A.3.: miRNAs that alter miR-34a antiproliferative
potential in EKVX cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-miR-892b

0.3714

0.7002

0.0151

0.4264

hsa-miR-4661-5p

0.4575

0.6689

0.0015

0.3594

hsa-miR-5693

0.4638

0.6005

0.0000

0.3845

hsa-miR-5093

0.4720

0.6852

0.0010

0.3354

hsa-miR-5582-5p

0.4752

0.3353

0.0000

0.4336

hsa-miR-4664-3p

0.4950

0.4897

0.0000

0.3861

hsa-miR-4725-5p

0.4972

0.5302

0.0000

0.3737

hsa-miR-5702

0.5275

0.4323

0.0000

0.3657

hsa-miR-5004-5p

0.5302

0.6703

0.0001

0.2859

hsa-miR-5009-5p

0.5322

0.5138

0.0000

0.3431

hsa-let-7a-2-3p

0.5999

0.7037

0.0018

0.1955

hsa-miR-3192-5p

0.6070

0.6760

0.0013

0.2058

hsa-miR-4687-5p

0.6177

0.6001

0.0017

0.2308

hsa-miR-4673

0.6177

0.7424

0.0197

0.1469

hsa-miR-6512-3p

0.6290

0.6705

0.0007

0.1870

hsa-miR-4768-3p

0.6343

0.6610

0.0003

0.1868

hsa-miR-766-5p

0.6393

0.5747

0.0000

0.2182

hsa-miR-4493

0.6715

0.5374

0.0005

0.1975

hsa-miR-33b-3p

0.6855

0.6237

0.0007

0.1534

hsa-miR-6715b-5p

0.7403

0.3834

0.0000

0.1613

hsa-miR-4471

0.7523

0.6522

0.0018

0.0734

hsa-miR-2355-3p

0.7674

0.8434

0.0433

-0.1545

hsa-miR-5591-5p

0.7690

0.6986

0.0002

0.0298

hsa-miR-6500-3p

0.7759

0.4015

0.0000

0.1228
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hsa-miR-1245b-5p

0.8012

0.8241

0.0011

-0.1459

hsa-miR-4633-3p

0.8143

0.5372

0.0000

0.0547

hsa-miR-4699-5p

0.8239

0.5848

0.0007

0.0301

hsa-miR-4430

0.8246

0.8320

0.0283

-0.1855

hsa-miR-5007-5p

0.8306

0.9123

0.0444

-0.5222

hsa-miR-5703

0.8414

0.8456

0.0088

-0.2341

hsa-miR-2114-5p

0.8485

0.6607

0.0016

-0.0272

hsa-miR-450a-2-3p

0.8557

0.5000

0.0001

0.0230

hsa-miR-4473

0.8611

0.8054

0.0053

-0.1726

hsa-miR-6503-5p

0.8703

0.7137

0.0001

-0.0820

hsa-miR-6505-5p

0.8788

0.7593

0.0005

-0.1307

hsa-miR-4643

0.8952

0.8733

0.0116

-0.3735

hsa-miR-4648

0.9163

0.8001

0.0079

-0.2195

hsa-miR-3157-3p

0.9388

0.6819

0.0011

-0.1295

hsa-miR-2392

0.9513

0.8536

0.0183

-0.3656

hsa-miR-4746-3p

0.9666

0.7140

0.0102

-0.1786

hsa-miR-4539

0.9785

0.8258

0.0245

-0.3266

hsa-miR-4651

1.0316

0.7482

0.0129

-0.2724

hsa-miR-378g

1.0370

0.8961

0.0447

-0.6203

hsa-miR-4677-5p

1.0768

0.8082

0.0230

-0.3929

hsa-miR-5100

1.1210

0.7519

0.0052

-0.3654

hsa-miR-4266

1.2003

0.8316

0.0069

-0.5604

hsa-miR-6089

1.3096

0.7202

0.0007

-0.5263
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Table A.4.: miRNAs that alter miR-34a antiproliferative
potential in Calu6 cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-miR-4700-5p

0.3216

4.1018

0.0000

0.4998

hsa-miR-4651

0.9163

3.8019

0.0000

-0.1139

hsa-miR-548ag

1.3142

1.1425

0.0000

-4.2001

hsa-miR-4537

0.7704

1.2057

0.0000

-2.4628

hsa-miR-610

1.0341

1.0581

0.0003

-9.5734

hsa-miR-3690

1.0396

0.2074

0.0004

0.6591

hsa-miR-3129-3p

1.1558

1.0899

0.0009

-6.3141

hsa-miR-4481

1.1163

0.3444

0.0318

0.7285

Table A.5.: miRNAs that alter miR-34a antiproliferative
potential in H460 cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-let-7a-2-3p

0.4313

0.3592

0.0001

0.9873

hsa-miR-5100

0.5719

0.4899

0.0017

0.9540

hsa-miR-4681

0.8217

0.5256

0.0020

0.7437

hsa-let-7c-5p

0.5255

0.5078

0.0030

1.0195

hsa-miR-4281

0.7396

0.5406

0.0037

0.8443

hsa-miR-6715b-5p

0.6642

0.5399

0.0365

0.9188
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Table A.6.: miRNAs that alter miR-34a antiproliferative
potential in H23 cells

miRNA

Single agent

In combination with miR-34a

P value

CI

hsa-miR-33b-3p

0.4574

0.4457

0.0005

0.9845

hsa-miR-4682

0.4827

0.4778

0.0001

0.9864

hsa-miR-10a-5p

0.5303

0.4580

0.0000

0.9217

hsa-miR-6512-3p

0.5708

0.4182

0.0001

0.8503

hsa-miR-6503-5p

0.5830

0.4419

0.0000

0.8560

hsa-miR-892b

0.6000

0.5387

0.0000

0.9310

hsa-miR-6500-3p

0.6095

0.3759

0.0000

0.7831

hsa-miR-6715b-5p

0.6287

0.4248

0.0000

0.7972

hsa-let-7c-5p

0.6309

0.5665

0.0050

0.9342

hsa-miR-766-5p

0.6771

0.4570

0.0011

0.7740

hsa-miR-597-5p

0.7048

0.6125

0.0089

0.9274

hsa-miR-648

0.7093

0.6165

0.0194

0.9296

hsa-miR-4633-3p

0.7253

0.3799

0.0000

0.6698

hsa-let-7a-2-3p

0.7476

0.6118

0.0021

0.8834

hsa-miR-2392

0.7501

0.5117

0.0031

0.7517

hsa-miR-450a-2-3p

0.7539

0.4797

0.0012

0.7170

hsa-miR-6505-5p

0.7892

0.5593

0.0012

0.7667

hsa-miR-3688-3p

0.7899

0.6825

0.0299

0.9818

hsa-miR-4253

0.7907

0.6790

0.0485

0.9726

hsa-miR-4664-3p

0.7933

0.4177

0.0001

0.6274

hsa-miR-5693

0.8062

0.4383

0.0000

0.6300

hsa-miR-4725-5p

0.8224

0.4528

0.0052

0.6253

hsa-miR-3157-3p

0.8240

0.5890

0.0028

0.7721

hsa-miR-380-3p

0.8387

0.6203

0.0001

0.8066
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hsa-miR-5582-5p

0.8389

0.5075

0.0000

0.6586

hsa-miR-4746-3p

0.8449

0.5570

0.0265

0.7082

hsa-miR-4472

0.8542

0.4978

0.0031

0.6336

hsa-miR-5093

0.8905

0.3321

0.0001

0.4763

hsa-miR-31-5p

0.8937

0.6179

0.0096

0.7474

hsa-miR-4471

0.8983

0.6547

0.0321

0.8111

hsa-miR-5702

0.9135

0.5883

0.0000

0.6817

hsa-miR-141-3p

0.9596

0.6288

0.0271

0.7004

hsa-miR-5004-5p

0.9668

0.4558

0.0001

0.4834

hsa-miR-5591-5p

0.9671

0.5559

0.0032

0.5845

hsa-miR-4673

0.9838

0.3927

0.0000

0.4196

hsa-miR-6127

1.0319

0.4026

0.0000

0.3782

hsa-miR-3662

1.0393

0.7010

0.0101

0.7800

hsa-miR-4768-3p

1.0504

0.5189

0.0030

0.4588

hsa-miR-3128

1.0627

0.6795

0.0159

0.7016

hsa-miR-5100

1.0883

0.5363

0.0132

0.4400

hsa-miR-4725-3p

1.0899

0.5991

0.0018

0.5213
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